Last Updated: September 12, 2026 TL;DR: Solomon Islands has no medicines register. The Pharmacy and Poisons Act has been in force since 1941 and licenses sellers and premises, not products, so there is no dossier to file. Section 43 makes the British Pharmacopoeia the standard of quality for every medicine sold. What actually binds a consignment is the importer's own licence, the Ministry's tender, and the donor rules attached to malaria and tuberculosis money. Key Takeaways There is no product registration system. The Act creates registers of pharmacists and of premises, and none for medicines. Anyone quoting a Solomon Islands registration timeline is describing something that does not exist. Section 43 makes the British Pharmacopoeia the standard of quality and composition for all medicines, and it was re-enacted in 1978 rather than merely inherited. The Indian Pharmacopoeia is named nowhere in the Act. Import lawfulness turns on the scope of the importer's own licence, not on the product and not on the foreign plant. No CPP, GMP certificate or overseas inspection appears anywhere in the statute. For Global Fund-financed artesunate and tuberculosis injectables, WHO prequalification or an Expert Review Panel recommendation is the route. For everything else the policy defers to the standard of the country of use. Introduction: What an Injectable Manufacturer in Solomon Islands Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Solomon Islands answers by not asking the question at all. There is no reliance list, and there is no product register for a reliance list to feed. The Pharmacy and Poisons Act, in force since 28 July 1941 and consolidated in the 1996 revised edition, creates a register of pharmacists and a register of premises. It creates nothing for medicines. That reframes the whole exercise. This is not a dossier market, and a supplier who offers you a registration timeline for it is describing a process that does not exist. Section 49 makes an import unlawful if the importer is not entitled under their licence to sell the thing being imported. The gate sits on the buyer, not on the product. What Sets a World-Class Injectable Manufacturer in Solomon Islands Apart Section 43 provides that the British Pharmacopoeia, in the edition for the time being in force, is the standard of quality or composition for all drugs and medicines. That is exclusive drafting — the standard, for all medicines — and it carries a detail worth noticing, because the section was re-enacted in 1978, the year of independence. Indian sterile plants routinely release to BP monographs, so this aligns well; an IP-only specification is the weak flank. The second thing to understand is where quality is actually policed, which is procurement rather than law. Public medicines move through the National Medical Store in Honiara to eighteen second-level stores and on to more than 350 service delivery points, free at the point of use. In 2023 the Ministry put bidding onto a digital platform and made expiry information and minimum delivery periods mandatory bid conditions. Those tender terms, not the 1941 statute, are where a manufacturer's certifications actually get read. Quality Systems Behind Every Sterile Injectable We Ship to Solomon Islands Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — not because Solomon Islands asks for one, but because a tender or a donor will. Two local realities shape the specification more than any rule does. Solomon Islands publishes no national stability condition; the WHO reference table places it at 30°C and 65% relative humidity, and that entry is derived from climate data rather than confirmed by the regulator, so we found no binding requirement and therefore claim none. We hold Zone IVb data because it envelopes that. And the last leg runs by boat, light aircraft and motorbike to clinics often staffed by one nurse, across nine provinces and ninety inhabited islands, which argues for long remaining shelf life far more than for cold chain. Working out whether Solomon Islands is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Solomon Islands for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Solomon Islands we can supply WHO-format GMP and pharmaceutical product certificates, BP-referenced release data and full stability packages for a tender file. What we cannot do is import, and no certificate we hold cures that: every licence in the Act attaches to a local person and local premises. We hold no Solomon Islands licence and recommend no partner we have not verified. The binding quality gate for part of the portfolio is a donor rule rather than a national one. The Global Fund accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it for vaccines only. But that gate applies solely to antiretroviral, anti-tuberculosis and antimalarial finished products; for everything else the policy defers to the standard of the country of use. Malaria is why this matters here: WHO recorded 147,145 presumed and confirmed cases in 2023, with 99% of the population living in a high-transmission area, and injectable artesunate has been national policy for severe malaria since 2018. The financing picture is unusual and easy to misread. Population was 838,645 in 2025; current health expenditure was 5.36% of GDP in 2023 at US$111 per head, putting the national total near US$89 million. Out-of-pocket spending was just 3.16% — among the lowest anywhere — but that figure is partly an artefact of the 33.87% financed externally in the same year, up from 27.37% in 2022. A third of the denominator is donor money, so the low household share is not by itself evidence of financial protection. We will not print a market-size figure: the two customs series we found disagree and both look implausible against US$89 million. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Solomon Islands recognise India's CDSCO or Indian regulatory approval? There is nothing to recognise it with. No instrument names any foreign medicines regulator — not CDSCO, and equally not the TGA, MHRA, US FDA or EMA — because the Act contains no agency-recognition mechanism and no product register. Where CDSCO status does bite is inside Global Fund money, and there it does not qualify. Is the Indian Pharmacopoeia accepted in Solomon Islands? Not on any published basis. Section 43 names the British Pharmacopoeia exclusively, as the standard for all drugs and medicines, and the Act's own schedule uses BP and BPC designations throughout. This is not fatal for an Indian supplier, because BP release is standard practice in Indian sterile plants — but an IP-only specification has no statutory footing, and a supplier claiming otherwise is reading something that is not there. Does a foreign manufacturer need a local partner in Solomon Islands? Yes, unavoidably. Every authorisation in the Act attaches to a local person or body corporate operating local premises: a Medicine Licence is granted to a licensed storekeeper and names the articles that may be sold, a Poisons Licence covers one place of business, and a body corporate dealing in drugs must trade under a registered pharmacist as superintendent. A foreign manufacturer holds nothing and can hold nothing. What does registration cost in Solomon Islands, and how long does it take? Neither question has an answer, and that is the finding rather than a gap. There is no registration, so there is no registration fee and no statutory decision clock anywhere in the Act — the only figures in the statute are legacy amounts that show its age. The Government's own trade portal publishes no medicines procedure at all. Confirm current practice directly with the Ministry of Health and Medical Services. What actually controls an injectable consignment arriving in Solomon Islands today? Three things, none of them a product approval. The importer's licence scope, under section 49, which makes the import unlawful if the licence does not cover the article. A discretionary power for the Under Secretary for Health to certify goods to Customs as not to be imported. And a separate Board licence for anything on the poisons list, which for an injectable portfolio notably includes insulin. A pharmacy permit is also reported in practice, though we found no instrument establishing one. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 2, 2026 TL;DR: Jamaica answers the question we always ask first — is there a list of regulators the country relies on, and is India on it — in a way no market in this series has quite matched: the regulation has no list, the procurement agency has one, and the regional reliance mechanism has another. The Food and Drugs Regulations of 1975 contain no reliance or abridged pathway at all; a new drug needs a certificate from the competent authority of the country of manufacture, five samples, a bioequivalence study for a generic, embassy-authenticated documents and a J$5,000 fee, and the Minister must respond within 120 days. In June 2025 the Minister announced a fast track for products already approved to United States, United Kingdom or European standards, but we found no implementing guideline or gazetted list and will not say whether one now exists. The National Health Fund's 2022 pharmaceutical tender, which supplies the public hospitals and Drug Serv pharmacies, accepts unregistered products only if registered by the Caribbean Regulatory System, the US FDA, Health Canada, the MHRA or the EMA, or WHO-prequalified; CDSCO is not on that list. The route for an Indian sterile injectable is therefore the ordinary Jamaican registration done well, and the commercial prize is a single public buyer that tenders internationally and lets manufacturers bid directly. Key Takeaways There is no reliance route in the regulation. Regulation 65 of the Food and Drugs Regulations 1975 requires a certificate from the competent authority of the country of manufacture or export, full quality and safety data, five finished-product samples with reference standards and, for generics, a bioequivalence study in at least twelve subjects. Regulation 68 obliges the Minister to say within 120 days whether the application is satisfactory. Documents must be authenticated by a Jamaican mission or, failing that, a British one. A named list exists, but at the procurement level. National Health Fund tender NHF-RX1/2022 accepts an item not registered in Jamaica only if it is registered by the Caribbean Regulatory System, the US FDA, Health Canada, the UK MHRA or the EMA, or is WHO-prequalified, and even then subject to Ministry approval. CDSCO is absent. Whether the next round repeats the clause is unknown; the safe assumption is that Jamaican registration is the ticket to the tender. The Caribbean Regulatory System is a recommendation, not a registration. CARPHA's 2020 guidance limits CRS to products holding a marketing authorisation from a reference authority or WHO prequalification; its reference list runs from ANMAT and ANVISA to the FDA, EMA, MHRA, PMDA and Swissmedic, and CDSCO is not on it. Member states are asked to decide within 60 days and may still demand a CPP, certificate of analysis and methods. The commercial gate is one buyer that tenders internationally. The NHF procures for state hospitals, health centres and 106 Drug Serv pharmacies; the 2023–2026 round awarded 61 contracts worth J$27 billion to 34 local and international suppliers, item by item on lowest evaluated price, with the distributor licence waived for manufacturers bidding directly. Out-of-pocket spending is 20.2% of health expenditure, so the State is the demand. Introduction: Why Jamaica Demands a Premium Injectable Manufacturer in Jamaica We open every market in this series by asking whether the country keeps a list of regulatory authorities whose approvals it will lean on, and whether India's CDSCO is among them. Jamaica gives three different answers depending on where you look, and the distinctions matter. In the law itself there is no list because there is no reliance route: the Food and Drugs Act of 1964 and the Food and Drugs Regulations of 1975 require every drug to be registered with the Ministry of Health before it is imported, manufactured or sold, and regulation 65 treats as a new drug anything not imported before August 1975 or new in its country of manufacture. The application must carry the formulation, route, dose, claims and contraindications, the potency, purity and safety testing, draft labels, finished-product and component samples, a certificate from the competent authority in the country of manufacture or export confirming the product is approved there, and a manufacturer's safety certificate. Regulation 68 then obliges the Minister to notify the applicant within 120 days whether the application is satisfactory. The Ministry's Pharmaceutical and Regulatory Affairs Department turns that into a practical checklist on its 2016 form: three copies of the summarised dossier, a clinical-pharmacology summary with a bioequivalence study in not fewer than twelve subjects for any generic, an original certificate of analysis on a recent batch with the method, five copies of the draft labels, five samples of the finished product with reference standards, an original WHO-format certificate of a pharmaceutical product, a list of countries where the product is approved or refused, and authentication of the documents by a Jamaican embassy or consulate or, where there is none, a British High Commission. The fee on that form is J$5,000 per presentation, and we do not know whether it has since been revised. Two conditions catch exporters out: products should have been on the market in the country of manufacture or export for at least a year before submission, life-threatening indications excepted, and where the innovator is not registered in Jamaica a generic is treated as a new drug. In June 2025 the Minister announced a fast track for products already approved to US, UK or European standards and acknowledged that 80% of dossiers are delayed for incompleteness. We found no implementing guideline or gazetted list of authorities, so whether a formal reliance list now exists is unknown in both directions — and for a premium injectable manufacturer in Jamaica the practical lesson is that a complete file, not a reliance argument, is what moves a registration. What Sets a World-Class Injectable Manufacturer in Jamaica Apart The dossier Jamaica asks for is not the CTD, and a supplier who simply ships a CTD will be returned. The form wants English, hard-bound and indexed copies of a summarised statement, and the department states that incomplete submissions are sent back. Within that structure the substance is familiar to any WHO-GMP manufacturer: full specifications and validated methods, stability data supporting the claimed shelf life in the Jamaican climate zone, and a certificate of analysis on a recent batch. The certificate of a pharmaceutical product is the pivot document — regulation 65(2)(g) requires it, and regulation 65(3) allows the Minister to accept an application without it only where detailed safety-test reports accompany the file. A GMP certificate does not appear on the registration checklist as we read it, because the CPP embeds GMP status, but the National Health Fund does require one for any unregistered reference-approved product it considers, so it belongs in the pack regardless. Once registered, importation runs on permits issued by the department, and the form asks for the name and address of a local representative where that differs from the applicant. We did not find a rule that the applicant must be a Jamaican-registered entity, and we did not read the Pharmacy Act's importer and wholesaler licensing provisions, so we neither assert nor deny that a local company is legally required; commercially, a Jamaican distributor is how the public tender is usually won, as the largest 2023 awards to LASCO Distributors, Cari-Med and Facey Commodity show. The registration's validity period and renewal cycle are not in the regulations as we read them, and the figures of twenty working days for a status approval and annual renewal appear only on consultancy websites, so we do not repeat them as fact. Neither Jamaica nor India is a PIC/S participating authority. Quality Systems Behind Every Injectable Supplied to Jamaica For a sterile injectable, Jamaica's requirements for potency, purity and stability testing translate into the same evidence a stringent inspector would want: media-fill records for the ISO Class 5 filling line, sterility and bacterial endotoxin testing by LAL, container-closure integrity, particulate matter, and HPLC or GC assay and impurity methods validated to ICH standards. Stability should be presented for the hot and humid zone Jamaica sits in, with ICH Q1A long-term and accelerated data rather than a temperate-zone extrapolation. Because the country-of-manufacture certificate is the anchor document, the CDSCO-issued WHO-format CPP must match the dossier exactly in strength, pack, manufacturing site and shelf life; a mismatch is the kind of small thing that costs a year. The regional layer deserves accuracy rather than enthusiasm. The Caribbean Regulatory System, hosted at CARPHA in Port of Spain since 2016 with PAHO and WHO, is described in its own guidance as a regional reliance mechanism that provides recommendations for market authorisation, verifying that a product is the same as one authorised by a reference authority or prequalified by the WHO. Its eligibility rule has no third route, and its reference-authority table — ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, COFEPRIS and the US FDA regionally, TGA, the EMA and EU authorities, MHRA, PMDA and Swissmedic beyond — does not include CDSCO. An Indian WHO-GMP product without WHO prequalification or a reference-authority authorisation cannot use CRS on the text as we read it; whether that table has been revised since November 2020 we do not know. And a CRS recommendation binds no one: national authorities are asked to decide within 60 days and may still require a CPP, certificate of analysis and methods. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Jamaica for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we know how to reshape them into the summarised, bound and indexed presentation Jamaica's form actually asks for, with the WHO-format CPP, certificate of analysis, five samples and reference standards, twelve-subject bioequivalence data where a generic requires it, and embassy authentication arranged in advance rather than discovered at submission. Our analytical package — HPLC, GC, LAL, Karl Fischer, ICH Q1A/Q1B stability — is written so that a 120-day review has nothing to send back, which in a system where the Minister has said most files are delayed for incompleteness is the single largest lever a supplier controls. The bilateral relationship is warm and the trade is real, without any regulatory shortcut attached. India's Ministry of External Affairs records bilateral trade of USD 116.73 million in 2023–24 and names pharmaceutical products first among India's exports to Jamaica; the Indian community of roughly five thousand is described as engaged primarily in pharmaceuticals and related businesses. The MEA brief lists cultural, research, aviation and foreign-service agreements but no pharmaceutical memorandum, mutual-recognition agreement or pharmacopoeia recognition, and a health memorandum reported as being finalised in 2019 we cannot confirm was signed. UN Comtrade puts India-reported HS 30 exports to Jamaica at USD 31.11 million in 2022, USD 32.05 million in 2023 and USD 30.36 million in 2024, with Jamaica reporting imports from India of USD 36.62 million in 2022 and about USD 33.80 million in 2024; we give both and average neither. Where the money is: Jamaica has 2.84 million people, gross national income per capita of USD 7,790 in 2025, current health expenditure of about USD 520 per person and 7.6% of GDP in 2023, and life expectancy of 71.6 years. Out-of-pocket spending was 20.2% of health expenditure in 2023, so the State is the buyer, and the State buys through one agency. The National Health Fund, which absorbed Health Corporation Limited's pharmaceutical warehouse in 2011, procures, stores and distributes for the public hospitals, health centres and 106 Drug Serv pharmacies against the Ministry's Vital, Essential and Necessary list, and processes about three million prescriptions a year. Its tenders are international competitive bidding on the GOJEP portal, open to bidders from all countries, awarded item by item on lowest evaluated price for 36-month contracts, with the distributor licence requirement waived for manufacturers bidding directly. The clinical hook is non-communicable disease: the national lifestyle survey reported one in three adults hypertensive and one in eight diabetic, which drives demand for the injectable antibiotics, anticoagulants, analgesics and emergency medicines a general hospital formulary carries. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Jamaica's list of recognised regulatory authorities? It depends which list. The Food and Drugs Regulations of 1975 have no reliance route and therefore no list. The June 2025 ministerial announcement named United States, United Kingdom and European standards for a fast track, and we found no implementing guideline, so whether a formal list now exists is unknown in both directions. The National Health Fund's 2022 tender accepts unregistered items registered by the Caribbean Regulatory System, the US FDA, Health Canada, the MHRA or the EMA, or WHO-prequalified; CDSCO is not on it. Neither is CDSCO a CRS reference authority. What exactly does a Jamaican new-drug application require? Under regulation 65 and the department's 2016 checklist: three bound copies of a summarised dossier covering formulation, route, dose, claims and contraindications; potency, purity and stability testing; a clinical-pharmacology summary with a twelve-subject bioequivalence study for a generic; an original certificate of analysis on a recent batch with the method; five draft labels; five finished-product samples with reference standards; an original WHO-format CPP; a list of approvals and refusals abroad; authentication by a Jamaican or British mission; and a J$5,000 fee, which may since have been revised. Can Farbe Firma use the Caribbean Regulatory System to enter Jamaica? Not without WHO prequalification or a reference-authority marketing authorisation. CARPHA's 2020 guidance restricts CRS to products holding an authorisation from one of its listed reference authorities or WHO prequalification, and CDSCO is not listed. Even a CRS recommendation is non-binding: Jamaica may still require a CPP, certificate of analysis and methods, and the NHF accepts CRS status only subject to Ministry approval. How do we sell to the public sector in Jamaica? Through the National Health Fund's international competitive tenders on the GOJEP portal, which supply the state hospitals, health centres and Drug Serv pharmacies against the VEN list. Bids are open to all countries, awarded per item on lowest evaluated price for 36 months, and a manufacturer bidding directly need not hold a distributor licence, though new suppliers need two institutional testimonials and a sample per unregistered product. In practice the largest awards go to Jamaican distributors, so a local partner is the usual route. How long does registration take and how long is it valid? Regulation 68 requires the Minister to notify within 120 days whether the application is satisfactory, and the Minister has publicly acknowledged that 80% of dossiers are delayed for incompleteness, so completeness is the real timeline. We did not find a validity period or renewal cycle in the regulations as read; the annual-renewal and twenty-working-day figures circulating online come from consultancy sites and we do not repeat them as fact. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 13, 2026 TL;DR: Cabo Verde's medicines regulator is ERIS, created by Decreto-Lei n.º 03/2019 de 10 de janeiro, which extinguished ARFA — so any guidance naming ARFA is stale. ERIS publishes two reference-entity lists and India's CDSCO is on neither by name. Its only possible entry runs through WHO's maturity-level list, where WHO's scope for CDSCO reads Vaccines (producing). The full dossier route is open, and the recognition rules set WHO GMP equivalence as the benchmark. Key Takeaways ERIS, the Entidade Reguladora Independente da Saúde, was created by Decreto-Lei n.º 03/2019 de 10 de janeiro and extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde. Guidance naming ARFA as the licensing authority describes a body abolished in January 2019. India's CDSCO appears on neither of the two reference-entity lists ERIS publishes. Its only possible entry is the 2025 annex's first category, a hyperlink to WHO's maturity-level list — where WHO's scope for CDSCO reads Vaccines (producing), with no medicines line. The list is not closed. Article 5 of Deliberação n.º 03/2019 admits another regulatory authority meeting the requirements of article 6, and article 6 sets the GMP benchmark at norms at minimum equivalent to those published by WHO. That is an argument to put to ERIS in writing, not an entitlement. Article 9(e) wants GMP evidence issued by an entity recognised by ERIS, and the only express fallback covers the active-ingredient maker alone. Physical import runs through the two licensed importer-distributors on the regulator's own register. Introduction: What an Injectable Manufacturer in Cape Verde Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Cabo Verde names a great many, twice over, and India is on neither list. ERIS publishes a reference-entity list dated 31 December 2020 and, beside it, the annex to Deliberação n.º 06/2025 de 14 de março, last updated in March 2025. Neither page says which one governs, and India's CDSCO appears on neither by name. There is one indirect door and it is narrower than it looks. The 2025 annex's first category is not a list ERIS wrote but a hyperlink to WHO's own list of authorities at maturity levels 3 and 4 — and WHO's entry for India's CDSCO carries the scope Vaccines (producing), with no medicines line beside it. Whether ERIS would accept a CDSCO decision on a non-vaccine product through that category is unresolved on the documents we have, and it is a question to put to the regulator in writing rather than to assume. What Sets a World-Class Injectable Manufacturer in Cape Verde Apart Start with the regulator, because half the guidance in circulation names a body that no longer exists. ERIS — the Entidade Reguladora Independente da Saúde — was created by Decreto-Lei n.º 03/2019 de 10 de janeiro, published in Boletim Oficial n.º 03, I Série, 1.º Suplemento, and it extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde in one stroke. The older regulations survive, because article 3(4) provides that legal references to ARFA are deemed made to ERIS. ERIS's own authorisation page still answers its legal-framework question by naming a 2014 deliberation that was expressly revoked in 2019, so read the instruments rather than the guidance. Then read article 5 of Deliberação n.º 03/2019 carefully, because it is the most useful sentence in the file. Recognition is available where an authorisation exists from an entity ERIS recognises or another regulatory authority that meets the requirements of article 6 — and article 6 asks only for an official authority that evaluates and authorises medicines, and one that guarantees by inspection that GMP norms at minimum equivalent to those published by WHO are respected. WHO GMP equivalence is ERIS's own express benchmark. A WHO-GMP holder has a textually grounded argument there; it has to be made in writing, and it is not self-executing. Quality Systems Behind Every Sterile Injectable We Ship to Cape Verde Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Dossiers are built in CTD structure with ACTD available — useful raw material here, though we found no provision making CTD or eCTD mandatory: article 10 asks for ERIS's own folder structure, distributed as a template from its site, and we found no e-submission portal. The stability requirement is stated in the regulation itself and it is the detail most often got wrong. Article 8(1)(i) requires studies adequate to the climatic zone of Cabo Verde, named as Zona Climática IVA in line with WHO guidance and conducted per ICH — not IVB. ERIS also accepts, as an alternative to completed results, a declaration that studies have been initiated together with the protocol, which is a real concession on timelines. On sample quantities we found no provision anywhere in the recognition regulation, and no guideline language calling any quantity approximate; we did not open the full-dossier regulation, where any such requirement would sit. Working out whether Cape Verde is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Cape Verde for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Cabo Verde we can supply the WHO-format CPP, the GMP and manufacturing-authorisation evidence, Zone IVA stability packages and the certified Portuguese translations the labelling texts need. The hardest gate is article 9(e), which wants GMP evidence issued by an entity recognised by ERIS, and whose only express fallback covers the active-ingredient maker alone. We hold no Cabo Verdean authorisation and recommend no partner we have not verified. Sterile injectables are structurally an import category here, and the register shows why. ERIS's list of licensed national operators, last updated 31 July 2026, names exactly one manufacturer in the country, Laboratórios INPHARMA, and we found no evidence that it manufactures sterile injectables — its own description of its production covers solid, liquid and semi-solid forms, and the only certification it names on its own site is ISO 9001. Physical import and wholesale distribution run through the two licensed importer-distributors on that same register, EMPROFAC, whose authorisation reference dates it to 1979, and SODIFAR, authorised in 2022. A foreign holder need not be seated in Cabo Verde: article 9(b) asks for proof of registration in the country where the applicant has its seat. The scale is small and the geography does the rest. Population is published at 491,233 by the national statistics institute for 2021 and at 527,326 by the World Bank for 2025 — about 7% apart, so we give both. Our own approximate calculation of national health spend, multiplying a 2025 population by a 2023 per-capita figure, lands between about US$142 million and US$153 million a year, and it is indicative only. Our own approximate count of the July 2026 register is 41 licensed private pharmacies across nine inhabited islands — twenty on Santiago, one each on Maio and Brava. For a 2 to 8 °C product that thin end of the network is a single point of cold storage per island, and every unit crosses water twice. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Is India's regulator recognised by Cape Verde? Not by name. India's CDSCO appears on neither of the two reference-entity lists ERIS publishes — neither the list dated 31 December 2020 nor the annex to Deliberação n.º 06/2025 updated in March 2025. The 2025 annex reaches India only indirectly, through a category defined by a hyperlink to WHO's list of authorities at maturity levels 3 and 4, and WHO's scope for CDSCO there reads Vaccines (producing), with no medicines line. Whether ERIS would accept a CDSCO decision on a non-vaccine product is unresolved on the documents we have. So is Cape Verde closed to Indian manufacturers? No. The full self-standing dossier route, AIM por processo completo under Deliberação n.º 06/2016 de 6 de maio, is open to any applicant whichever regulator authorised the product elsewhere — we did not obtain its procedural detail. And the recognition regulation carries its own catch-all: article 5 admits another regulatory authority that meets the requirements of article 6, and article 6 sets the GMP benchmark as norms at minimum equivalent to those published by WHO. A WHO-GMP holder has an argument to make there, in writing. What does registration cost in Cape Verde, and how long does it take? ERIS publishes 60,000 CVE for an especialidade farmacêutica and 25,000 CVE for a medicamento genérico, per medicine, where a medicine means name plus INN plus pharmaceutical form plus strength — and grouping strengths into one application does not reduce the number of fees. On timing, article 12 gives ERIS 90 calendar days from entry, extendable once by 60, but the clock suspends whenever the file is incomplete or ERIS queries the originating authority. It is a statutory period, not an elapsed-time forecast, and we found no published timeline for the full-dossier route. Must the dossier be in Portuguese, and must it be in CTD format? Portuguese is required for the application petition itself, and the summary of product characteristics, patient leaflet and labelling text must be supplied in certified Portuguese translation and additionally in editable form. Most of the technical file — the WHO-format CPP, quality-control methods and specifications, manufacturing authorisations, GMP certificates, the site flow chart — is accepted in Portuguese, English or French, so an English technical file is largely usable as it stands. We found no provision making CTD or eCTD mandatory, and no e-submission portal. Can the African Medicines Agency or ECOWAS get a product into Cape Verde? Not AMA, not yet. The treaty entered into force on 5 November 2021 and Cabo Verde acceded on 28 April 2023 and deposited on 13 July 2023, though it never signed — but we found no AMA-issued marketing authorisation, no published joint-assessment procedure and no submission portal, and AMA's own Director-General says it cannot yet function as a full single channel. ECOWAS is different: the West African joint assessment produces a WAHO recommendation, not an authorisation, and ERIS expressly names it on both of its recognition lists. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: September 13, 2026 TL;DR: Suriname has no standalone medicines agency. Marketing authorisation is granted by the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health, under an Ordinance of 8 May 1896 that is still operative as amended. Its fast track names eleven countries and four further categories, and India is not among them. The full dossier route stays open — on paper, in Dutch or English, filed by a licensed Surinamese importer. Key Takeaways There is no standalone drug agency. Authorisations come from the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health and whose own Code of Conduct describes it as a sub-commission of a Medicines Commission. The fast-track letter of 16 August 2022 names eleven countries and four further categories — fifteen numbered items. India is not among them, and we found no source placing CDSCO on the PIC/S members list, so that category does not reach India either. Instruction DVG 189/'25 of 19 February 2025 reserves a power to require an independent, GLP-compliant laboratory report applying to every batch, where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated. Registration is not permission to import. A separate import licence comes from the Ministry of Economic Affairs and is approved by the Pharmaceutical Inspectorate, and we found no published route for a foreign manufacturer to file in its own name. Introduction: What an Injectable Manufacturer in Suriname Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Suriname names eleven of them. A letter from the Registration Commission to importers, reference 019/2022 and dated Paramaribo, 16 August 2022, lists the Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden, and then four further categories. India is not among them, and we found no source placing CDSCO on the PIC/S members list either. That is a narrower finding than it sounds. Products from all other countries are expressly provided for, and the route they take is open. The Commission's own Code of Conduct says it assesses on the principle of reliance, so being off the reliance list means a heavier file and a slower lane rather than a closed door. Two of the four further categories — WHO prequalification, and a Caribbean Regulatory System recommendation — name no country at all and stay available product by product. What Sets a World-Class Injectable Manufacturer in Suriname Apart The first thing to get right is who the regulator is, because most secondary write-ups get it wrong. Suriname has no standalone medicines agency. Marketing authorisations are granted by the Registratiecommissie der geneesmiddelen, described by the Ministry of Health as a working organ of the Ministry of Health and by its own Code of Conduct as a sub-commission of a Medicines Commission, with at most seven expert members appointed by the President of the Republic. Its legal basis is the Ordinance of 8 May 1896 regulating the practice of pharmacy, operative text G.B. 1960 no. 77, amended several times since — amended, not repealed. The second is that the dossier is not the one you already have. The regulator calls its annex scheme the Common Technical Dossier, Appendices A to K — one word away from ICH's Common Technical Document, and not the same thing. It is an eleven-item Surinamese list running from quantitative composition of the actives to a statement from the competent authority in the country of production, and it asks along the way for data under tropical conditions and for labels and packaging material in six-fold. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place. Quality Systems Behind Every Sterile Injectable We Ship to Suriname Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — here they are the raw material for the A to K annexes rather than the filing itself, and the full route wants the WHO-GMP certificate of the API manufacturer as well as of the finished-product site. Two local details shape the work more than any of that. Both routes require a physical sample with the package leaflet enclosed, showing the country-of-origin registration number; the full route adds a certificate of analysis of that sample, and Annex J asks for samples of the finished dosage form and of the active ingredients in sufficient supply for analysis. For a short-dated parenteral that is a logistics exercise, and the regulator states that for now it is not possible to submit a registration file electronically. On cold chain we found no published Surinamese distribution or temperature guideline, and therefore claim none. Working out whether Suriname is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Suriname for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Suriname we can build the A to K annex set, supply the CPP and the WHO-GMP certificates of both the finished-product and the API sites, and generate the stability, release and sample data the file needs. What we cannot do is lodge it. The instructions are addressed to importers, the submitting party must hold a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department as an importer, and the cover letter must be signed by the importer's director and by the consultant pharmacist. We hold no Surinamese registration and recommend no partner we have not verified. The bilateral relationship is unusually warm, and it is routinely oversold. Diplomatic relations date from 1976, the Government of India's own embassy in Paramaribo puts the Indian-origin community at over 27% of the population, more than 550 ITEC training slots have been used, and lines of credit run cumulatively to the tune of US$60 million. On 4 June 2023 the Indian Pharmacopoeia Commission and Suriname's Ministry of Health signed a Pharmacopoeia MoU under which, in the IPC's own words, IP is accepted as a book of standards for medicines in the Republic of Suriname. That is standards recognition, not regulatory reliance. It did not place India on the 2022 fast-track list, which we found unamended, and it waives none of the CPP, the two GMP certificates, the annexes or the sample certificate of analysis. The numbers are small, and the honest version of them is worth more than a round one. India's embassy puts the population at about 620,000 while UN-based projections carried by population trackers put it nearer 645,000 for 2026, and we report both because they disagree. State supply runs through BGVS, the state medicines company established on 4 February 1983 and described on its own site as the country's largest importer and wholesaler of medicines; SZF, the social health insurer, publishes 271 medicines and consumables on which no patient co-payment may be charged. Our own approximate and partial count of the national medicines list, taken from its own export and covering entries from Abacavir to Doxycycline only, found about 202 product entries of which about 62 are injectable dosage forms — roughly three in ten. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Suriname recognise India's CDSCO or Indian regulatory approval? Not on the fast track. The Registration Commission's letter to importers names eleven countries — Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden — plus four further categories, and India is not among them; we also found no source placing CDSCO on the PIC/S members list. An Indian-made product can still reach the fast track product by product, through WHO prequalification or through a CARPHA Caribbean Regulatory System recommendation. Is the Indian Pharmacopoeia accepted in Suriname? Yes, as a book of standards. The Pharmacopoeia MoU signed on 4 June 2023 means, in the Indian Pharmacopoeia Commission's own words, that IP is accepted as a book of standards for medicines in the Republic of Suriname. Keep it in proportion: that is compendial recognition, useful in the composition and testing sections of a dossier. It is not regulatory reliance on CDSCO, and we found nothing designating CDSCO as a reference authority for Suriname. Can we submit a Suriname dossier in ICH CTD format? The regulator's published scheme is its own eleven-item annex list, which it calls the Common Technical Dossier, Appendices A to K — confusingly close to the ICH Common Technical Document, and not the same thing. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place, so plan for A to K. The regulator also states that for now it is not possible to submit a registration file electronically, so filings are hard copy. Will Suriname require independent batch testing of our injectables? It may. Ministry of Health instruction DVG 189/'25, dated 19 February 2025, reserves the power — where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated — to require an analysis report from an independent, GLP-compliant laboratory approved by the regulator of the country of manufacture, applying to every batch for which registration is sought. It defines highly regulated by PIC/S membership, WHO prequalification and WHO Listed Authorities, and allows a waiver on risk assessment. It is a reserved power exercised case by case, not a blanket rule. Can we register in Suriname without a local partner? The instructions are addressed to importers and state that the submitting party must have a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department of the Ministry of Health as an importer of medicinal products, with the cover letter signed by the importer's director and by the consultant pharmacist. We found no published route for a foreign manufacturer to file in its own name. Separately, a registered product still needs an import licence from the Ministry of Economic Affairs, approved by the Pharmaceutical Inspectorate. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: August 29, 2026 TL;DR: Mongolia has a genuine fast-track registration route, and an Indian manufacturer cannot use it. Under the last published version of the registration procedure, the accelerated pathway is reserved for products manufactured in, and approved by, a named list of thirteen “stringent regulatory authorities” built on ICH membership — and India's CDSCO is not among them. What is open is the ordinary route, which asks for registration in the country of manufacture plus three years on that market plus registrations in five further countries, a WHO-format CPP, a GMP certificate whose origin the text does not restrict, in-country laboratory testing at your cost, and a contract with a licensed Mongolian supply organisation, because a foreign manufacturer cannot hold the authorisation itself. Two things make the timing interesting: nearly half of Mongolian health spending is now out-of-pocket, which favours quality-assured low-cost injectables, and UNDP signed a three-year essential-medicines procurement project with the regulator in April 2026. This guide sets out what is verified, what was repealed, and what you must obtain from the regulator before you budget. Key Takeaways Mongolia's accelerated registration route is closed to an Indian file. Clause 3.9 of the procedure adopted by Minister of Health Order A/295 of 21 June 2019 named thirteen stringent regulatory authorities — the US FDA, the EMA and the European Commission, EU member state authorities, Japan's MHLW, Swissmedic, Health Canada, ANVISA, Korea's MFDS, Singapore's HSA, China's NMPA, Taiwan's TFDA and Australia's TGA. CDSCO is absent. Important caveat, and we would rather give it to you than have you find it later: that annex was repealed by Order A/206 of 26 May 2025, whose text we could not obtain, so treat the list as the last published version and ask MMRA for the current one. The ordinary route is the one that is actually open, and its barrier is documentary rather than scientific. Under the 2019 procedure an imported medicine had to be registered in its country of manufacture and either marketed there for at least three years and registered in at least five further countries, or registered in a country having a recognised stringent authority. Budget for the paperwork, not for a science argument. A foreign manufacturer cannot hold a Mongolian marketing authorisation directly. The registrant must be a licensed Mongolian supply organisation, an international supply organisation with a quality management system, a representative office entitled to represent the manufacturer, or a national manufacturer — and the dossier must contain the registration contract with that party. Changing the holder is treated as a minor change, so the partner decision is reversible more cheaply than most. Two market realities favour a WHO-GMP Indian supplier right now. Out-of-pocket spending rose from 39 percent of current health expenditure in 2022 to 48.8 percent in 2023 while spending per capita fell from US$448 to US$360, which is an affordability problem that quality-assured generics answer. And in April 2026 UNDP signed a three-year Procurement of Essential Medicines project with the regulator, adding a channel that runs on international procurement and quality-assurance standards. Introduction: Why Mongolia Demands a Premium Injectable Manufacturer in Mongolia Mongolia is a market of roughly 3.52 million people — the World Bank puts the 2024 population at 3,524,788 and gross national income per capita at US$5,380 — spread across the sixth-largest country in Asia with no coastline and exactly two neighbours. That combination does most of the work in explaining why supplying it is unlike supplying anywhere else. The health economics are moving quickly and not in a comfortable direction: current health expenditure per capita fell from US$448.24 in 2022 to US$359.61 in 2023, spending dropped from 8.85 percent of GDP to 6.07 percent, and the share paid directly by patients out of pocket rose from 38.95 percent to 48.80 percent. Almost half of what Mongolia spends on health is now paid at the point of care by the person receiving it. The disease burden that money has to meet is heavy. WHO's 2024 estimate puts tuberculosis incidence at 446 per 100,000 — and that figure carries a confidence interval of 240 to 713, which is wide enough that it should never be quoted without it. GLOBOCAN 2024 records 7,240 new cancer cases and 5,015 cancer deaths, a mortality-to-incidence ratio near 69 percent that points to late presentation, with liver cancer alone accounting for 2,230 cases. One methodological note, because it matters: IARC records no country-specific incidence source for Mongolia, so those incidence figures are modelled from national mortality data rather than observed in a registry. The regulatory picture is where most supplier content goes wrong, and it goes wrong in a predictable direction — by treating a fast pathway as an available one. Article 22.5 of the Law on Medicines and Medical Devices provides that medicines registered by an internationally recognised drug control institution shall be registered on an accelerated basis, and delegates the definition of that institution to ministerial order. The order then names a closed list. Under the procedure adopted by Order A/295 of 21 June 2019, clause 3.9 enumerated thirteen authorities, all of them anchored to ICH membership, and India's CDSCO was not one of them. Nor is WHO prequalification a general shortcut — clause 3.5 makes it an additional requirement for vaccines and tuberculosis medicines in WHO-PQ categories rather than a way around anything. This is now the fourth market in our recent country series where a regime that reads as liberal turns out to be shut to an Indian file, and the honest conclusion is the same each time: a liberal regime is not the same thing as an open one, and you should check whose name is on the list before you plan around the list. What Sets a World-Class Injectable Manufacturer in Mongolia Apart The ordinary registration route is open, and the discipline it demands is documentary. Under the 2019 procedure the dossier for an imported medicine ran to twenty-two enumerated items filed partly through the LICEMED system and partly on paper, in Mongolian, English or Russian, with certified translation for anything else. It is not an ICH CTD structure — the procedure prescribes its own list, and a team that arrives with modules and no mapping will spend weeks reformatting. Among the items: an original application signed and sealed by an authorised officer of the manufacturer; the registration contract with the Mongolian supply organisation; a manufacturer-certified copy of the GMP certificate; a certificate of a pharmaceutical product in WHO format, original or officially certified, with the summary of product characteristics attached; proof of registration in a stringent-authority country or in at least five other countries; a plant profile translated into Mongolian; finished-product certificates of analysis and analytical methods; stability data supporting the claimed shelf life; batch manufacturing instructions and a process flow with in-process controls; bioequivalence data where the dosage form requires it; colour artwork of primary and secondary packaging with physical samples; a package insert in Mongolian approved by the pharmacology sub-council; a post-marketing surveillance work plan; and — a genuinely unusual one — a price comparison study against domestic wholesale and retail prices. Three features of that regime deserve to be flagged before anyone budgets. First, in-country laboratory testing by an accredited laboratory under contract to the authority was mandatory, and expressly waived only for fast-track filings — which an Indian applicant cannot use. The cost of that testing, and the supply of reference standards and reagents, sat with the applicant. Mongolia inaugurated a new National Reference Laboratory for Medicines and Medical Devices on 16 June 2026 with WHO support and Pandemic Fund financing, so that capacity is being strengthened as we write. Second, the 2019 procedure contained a market-saturation rule with real commercial bite: a medicine would not be registered where the same active ingredient, strength and dosage form was already registered from more than ten manufacturers, again except on the fast-track. Check the register for your molecule before you spend anything. Third, decisions were taken by the Human Medicines Council sitting in session rather than by a desk reviewer, which changes how you prepare and when you can expect an outcome. We must be straight with you about the status of all of this: these clauses come from Annex 1 of Order A/295, which the state legal gazette records as repealed by Order A/206 of 26 May 2025, and we were unable to obtain the 2025 text. Any supplier quoting you today's Mongolian requirements with confidence should be asked which instrument they are reading. Quality Systems Behind Every Injectable Supplied to Mongolia On GMP, the accurate statement is narrower than the one you will usually be given, and the difference matters. A GMP certificate is a mandatory dossier item, submitted as a manufacturer-certified copy, and a WHO-format CPP is separately mandatory. The general registration criterion is simply that the manufacturer meets the requirements of Good Manufacturing Practice. What the text does not do is restrict whose GMP certificate counts. There is no clause naming WHO-GMP, no clause naming CDSCO or an Indian State Licensing Authority, and equally no clause excluding them. That is a permissive silence rather than an express acceptance, and it is a meaningfully better position than the one Uruguay's Decreto 18/020 creates, where the accepted issuers are enumerated and India is not among them. We would not tell you Mongolia formally accepts an Indian WHO-GMP certificate, because no instrument we read says so. We would tell you that nothing we read excludes it, and that you should get MMRA's current practice in writing. The landlocked question deserves an honest answer rather than a confident one. Mongolia borders China and Russia and nothing else, and a great deal of what circulates about routing, transit times and cold-chain lanes into Ulaanbaatar comes from freight-forwarder marketing rather than from any published rule. We are not going to give you a transit time we cannot source. What we can give you is a regulatory constraint that is verified and that we have not seen discussed anywhere: under the 2010 text of the Law on Medicines and Medical Devices, the import permit specifies the quantities, the manufacturer names, the period for crossing the border and the specific border port. The crossing point is fixed on the permit. For a consignment held at 2–8°C facing a delay at that port, you cannot simply divert to another one — and the same law penalises the import of expired product, which makes shelf-life-on-arrival a regulatory exposure and not merely a commercial one. Plan the remaining-shelf-life margin, the permit's crossing window and the excursion protocol together, because in Mongolia they are the same problem. Note also that these import-permit provisions are from the 2010 revised law; a revised Law took effect on 1 October 2024 and we have not read it, so confirm they stand. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Mongolia for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. What we bring to a Mongolian file is not a promise to shorten a timeline we do not control. It is the documentary depth the ordinary route actually asks for: a manufacturing history long enough to satisfy the marketed-for-three-years test, a registration footprint wide enough to satisfy the five-countries test, and the analytical package — HPLC and GC assay and impurity methods, LAL endotoxin testing, Karl Fischer moisture determination, sterility and container-closure integrity data — assembled so that a reviewer can follow it without a query round. Stability is run under ICH Q1A(R2) and Q1B protocols, which matters more than usual here because the shelf life you claim has to survive a long inland leg before it reaches a patient. We also build the file the way Mongolia asks for it rather than the way we already have it. Our master dossiers are maintained in CTD and ACTD structure for the markets that want them, and we do not pretend that structure is what Mongolia prescribes — the procedure sets out its own enumerated list, and our regulatory team maps our source documents onto that list item by item, including the ones that have no CTD equivalent at all. The price comparison study against domestic wholesale and retail prices is one of those. So is the post-marketing surveillance work plan, and so is the pharmacovigilance commitment that follows registration: safety reports every six months for the first three years, annually for the next two, and again at renewal. We prepare the plant profile for translation into Mongolian, we supply reference standards and reagents for the mandatory in-country laboratory testing at our own cost rather than leaving your partner to source them, and we hold the artwork and sample sets ready so the packaging review does not become the thing that stalls the file. Finally, we work through your structure rather than around it. Because a foreign manufacturer cannot hold the Mongolian authorisation, everything depends on the registration contract with a licensed Mongolian supply organisation or a representative office, and we draft to support that relationship rather than to constrain it — helped by the fact that a change of registration holder is treated as a minor change, so the arrangement is not a trap. Where the route is a procurement one rather than a commercial one, we can support that too: recent amendments to the medicines law and to the state procurement law created a legal basis for direct procurement from foreign manufacturers, the Ministry of Health contracted directly with a Korean manufacturer in November 2024, and in April 2026 UNDP and the regulator signed a three-year Procurement of Essential Medicines project applying international procurement and quality-assurance standards, with an initial focus on haemophilia. We will not tell you what that project's eligibility criteria are, because the announcement did not state them. We will tell you that a WHO-GMP dossier is the document such channels normally start from, and that India's own regulator holds WHO maturity level 3 while Mongolia's is not yet on WHO's ML3/ML4 list and is preparing to be benchmarked. India's mission in Ulaanbaatar was still pursuing recognition of Indian Pharmacopoeia standards as of the Ministry of External Affairs brief dated July 2026 — pursuing, not concluded. On the numbers, India reported US$8,263,672 of HS Chapter 30 exports to Mongolia in 2024 against US$7,582,642 in 2023, while Mongolia's own 2023 import figure from India was US$10,496,491, notably higher than India's export figure for the same flow. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Can an Indian manufacturer use Mongolia's fast-track registration route? On the last published text, no. Clause 3.9 of the procedure adopted by Minister of Health Order A/295 of 21 June 2019 named thirteen stringent regulatory authorities built around ICH membership, and neither India nor CDSCO appeared among them. The clause also required manufacture in a stringent-authority country as well as approval by one, excluded biologicals, vaccines, diagnostics and bioactive products, and required the product to sit on the WHO or Mongolian essential medicines list. Two honest caveats. First, that annex was repealed by Order A/206 of 26 May 2025 and we could not obtain the replacement, so ask MMRA for the current list before relying on this. Second, whether an Indian-made product that holds a US FDA or EMA approval qualifies is genuinely ambiguous on the wording, because the clause appears to require both manufacture and approval in a listed country. That is a question for Mongolian counsel, not for a blog. Does Mongolia accept a WHO-GMP certificate from an Indian plant? Nothing we read excludes it, and nothing we read expressly accepts it. A GMP certificate is mandatory, submitted as a manufacturer-certified copy, and a WHO-format CPP is separately mandatory. The registration criterion is stated simply as the manufacturer meeting GMP requirements, without naming an acceptable issuer. So the position is a permissive silence rather than a recognition. We flag it that way deliberately: a supplier who tells you Mongolia formally recognises Indian WHO-GMP is asserting more than the published text supports. Whether MMRA conducts an on-site inspection of an Indian plant, at what trigger and at what cost, we could not establish — though the 2019 fee schedule did carry a GMP expert's fee line item, which suggests some form of GMP assessment is charged for. Do we need a Mongolian partner, or can we register in our own name? You need a Mongolian party. Under the 2019 procedure the registrant had to be one of four things: a Mongolian medicines supply organisation holding a special licence, an international supply organisation with a quality management system, a representative office legally entitled to represent the manufacturer in Mongolia, or a national manufacturer. The dossier had to contain the registration contract with that party. A foreign manufacturer could not hold the authorisation itself. The mitigating detail is that a change of the registration-holding organisation is classed as a minor change and need only be registered with the regulator, so switching partners is administratively cheap by the standards of this region. Note that the 2024 revised Law introduced a new licensing framework which we have not read. How long does registration take and what does it cost? We are not going to give you a number we cannot source, and you should be wary of anyone who does. What is verified is that the fast-track route carried a decision period of up to three months; the total duration of the ordinary route was not something we could extract, and it is the ordinary route that applies to an Indian file. On fees, the 2019 procedure set a schedule payable in US dollars at the Bank of Mongolia rate and non-refundable, with separate line items for fast-track and ordinary registration of an imported medicine — but the current amounts sit in the 2025 procedure, which we could not obtain. You will also see a widely repeated claim that Mongolia runs a thirty-day and a sixty-day PIC/S track. We found no Mongolian instrument supporting it, it appears only in consultancy marketing, and it contradicts the three-month period the procedure actually states. Registration validity was five years under the 2019 text. What should we plan for on logistics, being landlocked between China and Russia? Plan around one verified constraint and treat everything else as a question for your freight partner. The constraint: under the 2010 text of the Law on Medicines and Medical Devices, the import permit names the specific border port and the period within which the crossing must happen. You do not have routing flexibility once the permit is issued, so a cold-chain consignment delayed at that crossing cannot simply be diverted. Combine that with the fact that importing expired product is penalised, and remaining shelf life on arrival becomes a compliance question rather than a commercial preference. What we will not tell you is transit times, corridor comparisons, customs clearance durations or whether Mongolia has formal Good Distribution Practice rules — we could not source any of it from an authoritative Mongolian source, and the freight-forwarder pages that dominate search results are not one. The Ministry of External Affairs itself attributes the modest scale of India–Mongolia trade to geographical transportation challenges, which is a fair summary of the problem. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 1, 2026 TL;DR: Namibia does not fit either pattern this series has been finding. It is not a market with a closed reference-country list that excludes India, and it is not a market with no list at all. The gazetted regulation creates the recognition hook in deliberately open language — registration granted by “other medicines regulatory authorities recognised by the Council” — and names nobody. The Council's actual list of recognised authorities lives in an online library we could not open, so we will tell you plainly that we do not know whether India appears on it, rather than guess in either direction. What we can tell you from the gazette itself is more useful than the list would be: regulation 45 couples the State tender to the registration file, so a medicine tendered internationally to the State can be supplied on an expedited basis once the manufacturing site has passed a WHO-guideline GMP inspection and the registration application is in. Namibia is a founding and currently active member of the ZaZiBoNa collaborative procedure, which is genuinely open to an Indian applicant but is work-sharing rather than register-once. And because out-of-pocket spending is only 7.49% of current health expenditure, the buyer here is the State, which makes the procurement regulations — not the dossier — the place where a foreign supplier actually wins or loses. Key Takeaways The recognition clause names nobody, and we could not read the list. Regulation 45(2)(c) of the 2008 Regulations under the Medicines and Related Substances Control Act 13 of 2003 recognises registration granted by “other medicines regulatory authorities recognised by the Council”, and regulation 45(4) permits an abbreviated review on the same basis. No country is enumerated in the gazette. The Namibia Medicines Regulatory Council's own site says the list of stringent regulatory authorities it aligns with sits in its E-library — which returned an empty page for us, as did the Council's home page, its guidelines page and the official copy of its CTD guideline. We therefore do not know whether India is on that list, and we say so rather than inventing a negative. It is the first question to put to the Registrar. The tender route and the registration file are deliberately coupled, and that is the most useful thing in the gazette. Regulation 45(1)(c) brings “any medicine tendered internationally to the State for supply to state hospitals and state health facilities” into the expedited process. Regulation 45(2) then permits supply where the manufacturing facilities have been approved by a GMP inspection conducted according to World Health Organization guidelines and a registration application has been submitted before supply, with a three-month review clock under 45(5). WHO GMP — not EU or PIC/S GMP — is the benchmark the regulation actually names, which is the right benchmark for an Indian WHO-GMP site. A local representative is mandatory and carries real answerability. Regulation 3(1)(b) allows the foreign manufacturer itself to be the applicant, so a registration need not be surrendered to a distributor. But regulation 3(5) requires an applicant not resident in Namibia to appoint a local representative, and regulation 3(6) provides that the representative “will be answerable to the Council in respect of the quality, safety and efficacy of the medicine”. Regulation 3(4) separately requires a named pharmacist or technical representative responsible for liaising with the Council. Both appointments are structural, not administrative. The commercial gate is procurement, and it is tilted. With out-of-pocket spending at 7.49% of current health expenditure in 2023, Namibia is not a cash-pay market. Under the Public Procurement Regulations a bid security is mandatory above N$500,000, and where that security is a foreign bank guarantee the bidder must supply a counter-guarantee from a Namibian commercial bank. Public entities must encourage joint ventures and must give more weight to entities demonstrating that more than 60 per cent of key employees are Namibian, while preference beneficiaries may be exempted from bid security altogether. A foreign bidder is not excluded, but it is structurally disadvantaged unless it partners locally. Introduction: Why Namibia Demands a Premium Injectable Manufacturer in Namibia For several markets in this series the opening research question has produced one of two answers. Either the country publishes a closed list of regulators whose approvals it will lean on and India is not among them, or — as Qatar turned out — there is no list at all and the constraints sit somewhere else entirely. Namibia produced a third answer, and it is the least comfortable of the three to write about honestly. The recognition hook exists and is gazetted, but it names nobody. Regulation 45 of the 2008 Regulations made under the Medicines and Related Substances Control Act 13 of 2003 permits supply where “a registration has been granted by other medicines regulatory authorities recognised by the Council”, and permits an abbreviated medicine review process where another authority has already registered the product for the purpose applied for. Who those authorities are is not in the gazette. It is an administrative matter for the Namibia Medicines Regulatory Council. We tried to read that list and failed. The Council's registration page states that the list of stringent regulatory authorities and organisations it aligns with can be found in its E-library; the E-library returned a completely empty page, as did the Council's home page, its medicine registration overview, its guidelines index and the official copy of its own CTD submission guideline, which we ultimately had to read from a mirror. We are telling you this because the alternative is worse. A confident sentence saying India is not recognised by Namibia would be an invented negative, and a confident sentence saying it is would be wishful. What we will do instead is set out what the gazette itself says, which is enough to plan around, and name the E-library list as the first question a serious buyer should put to the Registrar in writing before spending money on a file. What Sets a World-Class Injectable Manufacturer in Namibia Apart Start with the dossier, because it is straightforward and it is one of the few things in this market that is. Namibia works in the Common Technical Document format, not the ASEAN variant, under a guideline for submission of applications for registration of pharmaceuticals for human use in CTD format that is built on ICH structure together with the World Health Organization's multisource generics guidance. Module 1 is Namibia-specific, and we will be honest that we could not open the Module 1 specification itself — the mirror we found returned a bot-block — so we cannot tell you its exact contents. Submissions go in electronically on disc with text-selectable PDFs for all five modules plus editable files for the quality overall summary and the templates, a screening fee is paid first and the application fee follows once screening is passed, and the applicant has ninety days to answer queries. Bioequivalence data is mandatory for generics, with biowaivers available for immediate-release solid orals in BCS Class I and III and narrow-therapeutic-index products excluded. The Council sits four times a year. The documentary requirements for a foreign manufacturing site are precise and, for a WHO-GMP holder, entirely reachable. Regulation 5(e) requires a certified copy of the manufacturing licence together with a current good manufacturing practice certificate from the medicines regulatory authority of the country of origin. Regulation 5(f) requires a site master file. Regulation 3(2) requires a foreign applicant to prove registration as a pharmaceutical manufacturer with its home regulator and to hold a current GMP certificate from that regulator, and regulation 3(3) gives the Council express power to make such investigations as it considers necessary to verify any of it. Regulation 43(2) goes further and provides that the Council “must ensure through regular inspections” that all medicines registered in Namibia are manufactured according to WHO current GMP guidelines. Note carefully what that means: a home-regulator GMP certificate is a required document, not a substitute for inspection. Anyone who tells you a WHO-GMP certificate closes the GMP question in Namibia has read regulation 5(e) and stopped there. Quality Systems Behind Every Injectable Supplied to Namibia There are two documentary points where we will not pretend to certainty. The first is the certificate of a pharmaceutical product. Regulation 5(e) speaks of a manufacturing licence and a GMP certificate; we found no explicit CPP requirement anywhere in the 2008 Regulations. A CPP requirement may well sit in the Module 1 specification or the application form annexure we could not open, so we are not saying Namibia requires one and we are not saying it does not. Prepare one, because it is cheap insurance and every neighbouring market wants it, but do not let anyone tell you the regulation demands it on the strength of a summary. The second is legalisation. The regulations say “certified copy” and specify no notarisation, apostille or embassy attestation chain, and we did not verify Namibia's status under the Hague Apostille Convention. That is a question for the Registrar, not for an article. A third point is a genuine conflict between the gazette and current practice, and it is the kind of small thing that wastes a shipment. Regulation 5(a) of the 2008 Regulations requires three samples of the medicine in the smallest of each of the package forms. The Council's own website and its published FAQ both say one sample per strength in the smallest pack size. Those are not the same requirement, and the gazetted regulation has not obviously been amended to match the practice. Confirm in writing before you ship, and note the one piece of good news attached to it: the Council states that no import licence is needed for registration samples. On timelines, we will give you the Council's own words rather than a consultant's estimate, because they are more honest than anything we could construct: “There are currently no specific timelines for the registration of medicines, owing to the current backlog of applications.” The only statutory clock we found anywhere is the three months in regulation 45(5), and it applies to the tender route. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Namibia for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, maintain the analytical infrastructure a regulator expects to see behind a file — HPLC, GC, LAL endotoxin testing, Karl Fischer moisture determination and ICH Q1A and Q1B stability programmes — and we are used to markets where the manufacturer is the applicant of record rather than a name on someone else's certificate. Namibia's regulation 3(1)(b) is precisely such a route, and we would encourage any buyer to think carefully before giving that position away, because regulation 3(6) makes the local representative answerable to the Council for quality, safety and efficacy, and you want that person to be someone you chose rather than someone who chose you. The regional dimension deserves accuracy rather than enthusiasm. Namibia is a founding member of the ZaZiBoNa collaborative medicines registration procedure — it is the “Na” — and it is currently classified as active, meaning it has the capacity to conduct both assessments and GMP inspections. Eligibility is dossier-based, not domicile-based, so there is no visible barrier to an Indian applicant. What it is not is a single registration valid across Southern Africa. Entry requires an identical dossier filed in a minimum of two participating countries with the national fees paid in each, and the Council's own description of the outcome is that individual countries “can rely on this decision at country level to subsequently register or not register a product in the country based on local regulatory requirements”. Rely, not bind. Treat ZaZiBoNa as a way to make one assessment do the work of several, which is real value, and not as a passport, which it is not. It is also worth knowing that the World Health Organization conducted an assisted self-benchmarking of the Council in Windhoek in October 2025 and described it as advancing toward maturity level 3 — so not yet there, and not a WHO Listed Authority, but moving, with a new Medicines and Related Substances Control Bill drafted to replace the 2003 Act and an ISO/IEC 17025 accredited national quality control laboratory now in place. Which brings us to where the money actually is, and it is not the dossier. Namibia spent about 9.48% of GDP on health in 2023 at roughly USD 397 per person, against a population of about 3.09 million and gross national income per capita of about USD 4,340. But out-of-pocket spending was only 7.49% of current health expenditure. That single number tells you the shape of the market: this is a public-budget and medical-aid market, not a pharmacy-counter one, and the disease burden points the same way, with adult HIV prevalence around 9.0% and tuberculosis incidence around 422 per 100,000 in 2024. The buyer is the State, and the State buys under the Public Procurement Act and its regulations, where the asymmetries are explicit. A bid security is mandatory above N$500,000 and a foreign bank guarantee must be backed by a Namibian commercial bank counter-guarantee. Public entities must encourage joint ventures with Namibian bidders and must give more weight to entities showing more than sixty per cent Namibian key employees. Preference beneficiaries can be exempted from bid security entirely. We could not read the annexures carrying the threshold values and the margin of preference, because they are embedded images, and we are not going to quote numbers we did not see. But the direction is unambiguous, and the strategic conclusion follows from it: in Namibia the registration file is the easy half. Build the local partnership first, because regulation 45 will let the tender pull the registration along behind it, and the procurement rules will decide the outcome long before the Council does. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Namibia's list of recognised regulatory authorities? We do not know, and we are not going to pretend otherwise. The gazetted regulation — regulation 45(2)(c) and 45(4) of the 2008 Regulations under the Medicines and Related Substances Control Act 13 of 2003 — refers only to “other medicines regulatory authorities recognised by the Council” and enumerates nobody. The Namibia Medicines Regulatory Council's registration page states that the list of stringent regulatory authorities and organisations it aligns with is held in its E-library. That E-library returned an empty page for us on every attempt, as did several other pages on the same portal, which appears to render its content in a way our tools could not retrieve. So the honest position is that the list exists, we did not see it, and India's status on it is unknown in both directions. Put it to the Registrar in writing before you budget a file around it. Note separately that the World Health Organization collaborative registration procedure for prequalified products is explicitly encouraged by the Council, and that route does not depend on the list at all. Will our WHO-GMP certificate from CDSCO be accepted, or will the Council inspect us? Both propositions are true at once and the distinction matters. Regulation 5(e) requires a certified copy of the manufacturing licence together with a current GMP certificate from the medicines regulatory authority of the country of origin, and regulation 3(2) requires a foreign applicant to prove home-regulator registration and hold a current GMP certificate. So the document is required and a CDSCO-issued WHO-GMP certificate is the document the regulation contemplates. But regulation 3(3) gives the Council express power to make whatever investigations it considers necessary, and regulation 43(2) obliges it to ensure through regular inspections that every medicine registered in Namibia is manufactured to WHO current GMP guidelines. The certificate is therefore a required input, not a waiver of inspection. Worth knowing too that the benchmark named in the regulation is WHO GMP rather than EU or PIC/S GMP, which is favourable positioning for an Indian site — and that neither Namibia nor India is a PIC/S participating authority or applicant, so no PIC/S-based shortcut exists in either direction. Does ZaZiBoNa mean we can register once and sell across Southern Africa? No, and this is the most common misunderstanding about the procedure. Namibia is a founding and currently active member, and active status means it can carry out both assessments and GMP inspections. Eligibility is based on the dossier, not the applicant's nationality, so an Indian manufacturer can participate. But the procedure is work-sharing, not mutual recognition. To enter it you must submit an identical dossier to a minimum of two participating countries and pay the national registration fees in each. When the joint assessment concludes, the Council's own description is that individual countries can rely on the decision to subsequently register or not register the product based on local regulatory requirements. National registration remains a separate act in every country. The genuine value is that one assessment can support several national decisions, which compresses cost and calendar across a regional launch. The value it does not have is a single Southern African marketing authorisation, because no such thing exists. How long does registration take and what will it cost? On timing we will quote the Council rather than estimate: its published FAQ states that there are currently no specific timelines for the registration of medicines, owing to the current backlog of applications. Any figure you are given in months for the ordinary route is somebody's guess. The single statutory clock we located is the three-month review period in regulation 45(5), which attaches to applications made under the tender-linked expedited route, and that is a strong argument for entering through a State tender rather than through an ordinary filing. On cost we have to be equally direct: fees are set by a statutory schedule published in Government Gazette 7608 in 2021, which is held in the same E-library we could not open, so we have no verified registration, screening, fast-track or collaborative-procedure fee to give you. The one figure published in the Council's FAQ is N$1,500 for variations that require a new registration certificate, with certain minor variation types exempt. Budget from the gazette once you have it, not from an article. Is Namibia a tender market, and what does that mean for a foreign supplier? Overwhelmingly, yes. Out-of-pocket spending was 7.49% of current health expenditure in 2023, which means almost nothing is bought at a pharmacy counter with a patient's own money; the State and the medical aid schemes are the demand. Public buying runs under the Public Procurement Act 15 of 2015 and its regulations, with the Central Procurement Board conducting bidding above the public-entity threshold and the Ministry of Health's Central Medical Stores as the warehousing and distribution arm. Three features of the regulations shape a foreign bid. A bid security is mandatory where the contract value exceeds N$500,000, and if it takes the form of a foreign bank guarantee the bidder must also provide a counter-guarantee from a Namibian commercial bank. Public entities must encourage joint ventures between foreign entities and Namibian bidders and must give more weight to entities demonstrating that more than sixty per cent of key employees are Namibian. And bidders qualifying for national preference may be exempted from bid security altogether. None of that bars a foreign supplier, but all of it argues for a local partner rather than a direct bid. We were unable to read the annexures containing the threshold values, the standard security rates and the margin of preference, because they are embedded images in the published regulations, so confirm those figures from the gazette before you model a bid. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 27, 2026 TL;DR: Mauritania imports essentially all of its medicines, and the route in is narrower and more specific than most exporters expect. A marketing authorisation, the Autorisation de Mise sur le Marche, is granted by the Minister of Health under Loi n° 2004/036 and is valid for five years; the same law carves out a separate, fee-exempt registration procedure for essential medicines selected through public tender, which is the door most volume actually walks through. That tender is run by CAMEC, the state purchasing centre, and its 2025 international call prequalified product-and-manufacturer pairs for a three-year approval with physical samples required at submission. The law also requires the importing company to be pharmacist-owned with a legally liable pharmacien responsable, so a foreign manufacturer cannot import on its own account. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the sample, analytical and stability package that a Mauritanian partner needs to enter that tender credibly. Key Takeaways The tender route is a separate legal pathway, not a shortcut through the normal one. Article 26 of Loi n° 2004/036 requires an Autorisation de Mise sur le Marche before any medicine may be imported, sold or even distributed free of charge – and then states in the same article that essential medicines selected through a public tender procedure are registered under a separate procedure fixed by the Minister and are exempt from registration fees. For a generic injectables manufacturer that single sentence reorders the whole commercial plan: the question is not only how to register, but whether the molecule is on the national essential medicines list and inside a CAMEC tender cycle. CAMEC prequalifies the product and the factory together, for three years at a time. Its 2025 international call, reference AOIPQ N°2025/001/CAMEC, was explicitly a prequalification of suppliers of essential generic medicines under INN and of medical consumables, building a validated list of product-and-manufacturer couples. The approval runs three years and lets the holder bid in restricted consultations during that period. Physical samples had to accompany the prequalification dossier. A manufacturer that cannot supply representative samples and defend them analytically does not get onto the list, and being off the list means being invisible for three years. You cannot import into Mauritania on your own account. Articles 44 and 48 of the same law require every pharmaceutical import and wholesale establishment to hold an opening authorisation from the Minister of Health, to be owned by one or more pharmacists or to be a company in whose capital Mauritanian pharmacists may hold a share, and to have a pharmacien responsable as technical director on a Ministry model contract, personally liable. Each separate establishment needs its own authorisation and its own pharmacien delegue. The practical consequence is that the quality of your Mauritanian partner is part of your regulatory file, not a separate commercial question. Much of the operating detail is simply not published, and honest suppliers say so. Article 28 leaves the actual conditions for granting an authorisation to a ministerial arrete, and that arrete is not publicly available; nor is the fee schedule, nor a review timeline, nor a published register of authorised medicines. Mauritania has not signed the African Medicines Agency treaty and its regulator has not been benchmarked under the WHO maturity framework, and because Mauritania left ECOWAS in 2000 it is outside the WAHO/ECOWAS medicines harmonisation work as well. Any supplier quoting you a confident Mauritanian dossier format or approval time is quoting something they cannot source. Introduction: Why Mauritania Demands a Premium Injectable Manufacturer in Mauritania Mauritania is a country of about 5.3 million people with a gross national income per head of roughly US$2,210, spending around 4.34 per cent of GDP on health, or about US$92 per person per year, with close to 44 per cent of that coming straight out of patients' pockets – all World Bank figures, the health-spending ones for 2023. Those numbers set the commercial temperature of the market. It is a price-sensitive, tender-led, public-sector-dominated environment, and it is one where a supplier's landed cost matters as much as its dossier. It is also a market with no publicly documented domestic sterile manufacturing: a 2022 investment convention for a first pharmaceutical plant in Nouakchott was announced by the government, but nothing published confirms it was built or licensed, and the country continues to import. The clinical demand is real and it is disproportionately injectable. WHO's 2024 malaria country profile for Mauritania, with data validated by the country in November 2024, records that 64 per cent of the population – about 3.2 million people – live in high-transmission areas, that 108,415 presumed and confirmed cases were reported against a WHO estimate of 192,600, and that national policy for severe malaria is injectable artesunate. Maternal mortality stood at 381 per 100,000 live births in 2023, which translates into demand for oxytocics, magnesium sulphate, antibiotics and resuscitation fluids. And in September 2025 the Ministry of Health confirmed the award of what regional press described as the country's first international tender dedicated to haemodialysis, a grouping of Japan's NIPRO with the Mauritanian company NOSOMACI, an investment reported at more than six million euros in a segment the same reporting described as previously under monopoly and little modernised. Sterile injectables sit in the middle of all of it. What Sets a World-Class Injectable Manufacturer in Mauritania Apart The first differentiator is knowing which of the two doors you are walking through. The normal route is the Autorisation de Mise sur le Marche granted by the Minister of Health, valid five years and renewable, with any variation however minor requiring prior authorisation. Applications are assessed with the advice of the Commission Nationale des Medicaments, whose statutory criteria under Article 21 are unusually explicit about commerce as well as science: therapeutic interest and efficacy, safety in normal use, quality, the ex-works wholesale price in the exporting country, and whether the product holds an authorisation in its country of origin – with that last requirement expressly waived for generics. A manufacturer that arrives with a defensible Indian price position and a clean generic story is answering the question the Commission is actually asked. The second is understanding what a refusal looks like, because the law tells you. Article 30 requires any refusal to be reasoned and notified within thirty days, and lists among the grounds that the manufacturing and control conditions are not compliant, or that the methods of manufacture and control are inadequate to guarantee quality at batch scale. That is a manufacturing-capability test, not a paperwork test. It is reinforced downstream by Article 126, which requires pharmacy inspection to visit every establishment at least once a year. A supplier whose batch records, process validation and analytical method validation would survive that reading is a supplier whose file is difficult to refuse on the stated grounds. Quality Systems Behind Every Injectable Supplied to Mauritania Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Environmental monitoring, operator qualification, media fills, filter integrity testing and container-closure integrity are run as a continuous programme rather than as a batch-release afterthought. Finished product is released against IP, USP, BP and EP monographs using HPLC and GC for assay and related substances, Karl Fischer for water content where the presentation demands it, and LAL for bacterial endotoxins, with sterility testing on every sterile lot. The reason this matters specifically for Mauritania is CAMEC: a prequalification in which physical samples are submitted alongside the dossier is decided partly on what the vial does in a laboratory, not only on what the file says about it. Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B, in the actual container-closure system that will ship, and defended on hot and dry conditions appropriate to Saharan storage and long overland distribution rather than on temperate data borrowed from another market. Because Mauritania has published no dossier format, we build the file so that it can be presented in CTD or ACTD structure on request and reorganised into whatever the Ministry's arrete specifies once it is seen, rather than assuming a format and having to rebuild. Certificates of analysis, the manufacturing licence and the WHO-GMP certificate are issued in a form that survives chamber of commerce, Ministry of External Affairs and embassy legalisation without needing reissue. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Mauritania for Global Buyers The commercially decisive fact about Mauritania is that one buyer shapes the market. CAMEC – the Centrale d'Achat des Medicaments, Equipements et Consommables Medicaux – was created by decree in 2002 as a mixed-economy company and converted by decree in 2010 into a wholly state-owned societe nationale with a capital of 137,025,000 MRU, operating on a non-profit cost-recovery basis with its own special procurement commission. Its public catalogue distinguishes monopoly medicines, essential medicines and consumables. Alongside the three-yearly prequalification it publishes a running stream of ad-hoc award records through 2026, which tells a supplier something useful: there is off-cycle business, and being prequalified is what makes you reachable when it appears. India is already a substantial supplier and the relationship is commercial rather than treaty-based, which is worth stating plainly because it is often implied otherwise. On UN Comtrade figures India exported about US$10.5 million of HS Chapter 30 pharmaceutical products to Mauritania in 2024 and about US$11.9 million in 2025. The Embassy of India in Nouakchott, which opened in June 2021, records in its bilateral brief of 9 June 2025 that President Droupadi Murmu made the first-ever State visit to Nouakchott in October 2024 and lists the four bilateral agreements in force – a diplomatic visa waiver, a foreign-office consultations protocol, a diplomatic-training memorandum and a cultural exchange programme. There is no pharmaceutical or regulatory memorandum between the two countries. Nothing about being Indian shortens a Mauritanian file; what shortens it is the file itself. Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which suits a market where the same molecule may need to serve a CAMEC tender line under INN and a private importer's own-label presentation at the same time. We supply dry powder vials, liquid ampoules and vials, lyophilised presentations and small-volume parenterals across anti-infectives, analgesia, anaesthesia, oncology support, emergency and critical care; we support own-label and technology-transfer programmes; and we prepare CTD and ACTD dossiers, DMF and CEP-referenced API documentation, and legalisation-ready certification for more than 30 export markets. For a Mauritanian importer the practical offer is a partner who can produce representative samples on request, defend them against a monograph, and hold the specification steady across a three-year prequalification window. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Who regulates medicines and injectables in Mauritania? The Ministry of Health. Under Loi n° 2004/036 the Autorisation de Mise sur le Marche is granted by the Minister of Health, on the advice of the Commission Nationale des Medicaments, whose secretariat is the pharmacy directorate and whose membership includes the Inspector General of Health, the director responsible for pharmacy and representatives of the national professional order. Note that the directorate's name appears differently in different official sources – the Ministry's own site uses Direction de la Pharmacie et des Laboratoires, while the African Medicines Agency's published ratification dataset records it as Direction du Medicament et des Laboratoires – and we have not found a decree that settles it. Inspection sits with the Inspection Generale de la Sante, which is required to visit every establishment at least annually. How long does a Mauritanian marketing authorisation last, and what does it cost? The authorisation is valid for five years and is renewable, and any variation, however minor, requires prior authorisation. On cost we will not give you a number. Article 29 provides that the application carries a fee whose amount is fixed by a joint order of the Ministers of Health and Finance, and we could not locate that order or any published tariff. What the law does state clearly is that essential medicines selected through the public tender procedure are registered under a separate procedure and are exempt from registration fees, which is a material commercial difference between the two routes. Does Mauritania require a CTD dossier, a WHO-GMP certificate or a WHO-type CoPP? We cannot tell you, and neither can anyone else from published sources. Article 28 leaves the conditions for granting an authorisation to a ministerial order that is not publicly available, and the registration articles of the 2004 law do not themselves mention Good Manufacturing Practice certification, the WHO certification scheme or any dossier format. In practice a Mauritanian importer will ask for a WHO-GMP certificate and a certificate of pharmaceutical product because that is what regional practice and tender documents generally expect, and CAMEC's prequalification dossier is not published either. We supply both as a matter of course and build the technical file so it can be presented in CTD or ACTD structure. What we will not do is state a requirement we cannot source. Can a foreign manufacturer import directly, or is a local partner required? A local partner is effectively required. Articles 44 to 48 of Loi n° 2004/036 require every pharmaceutical import and wholesale establishment to hold an opening authorisation from the Minister of Health, and require that the company be owned by one or more pharmacists, or be a commercial company in whose capital Mauritanian pharmacists may hold a share, with a pharmacien responsable as technical director on a Ministry model contract who is personally liable. Every separate establishment needs its own authorisation and its own delegated pharmacist, and importers may supply only other authorised wholesalers or persons licensed to dispense. Named-patient imports of unregistered medicines for serious disease, and donation imports, each require a specific authorisation from the director responsible for pharmacy. What makes Farbe Firma a suitable injectable manufacturer for Mauritania? Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Mauritania that translates into four concrete things. We can produce representative physical samples for a CAMEC prequalification and defend them against IP, USP, BP or EP monographs using validated HPLC, GC, Karl Fischer and LAL methods. We generate ICH Q1A(R2) and Q1B stability data on hot and dry conditions matched to Saharan storage and overland transit. We prepare CTD and ACTD dossiers and legalisation-ready certification that survives the chamber, ministry and embassy chain without reissue. And we hold a specification steady across a three-year prequalification window, which is what an approval tied to a product-and-manufacturer pair actually requires. Contact info@farbefirma.com to discuss a specific molecule, tender line or own-label programme. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 11, 2026 TL;DR: Guyana names the regulators it leans on — the United States, Canada, the United Kingdom and Australia — and India is not among them. But it leans harder than any other CARICOM state on the Caribbean Regulatory System, which accepts a WHO-prequalified finished product as an eligibility route. Guyana has registered 164 CRS-recommended products since October 2017, against Haiti's five. The door is open; it is simply not the door marked CDSCO. Key Takeaways Guyana's Food and Drug Department states it relies on assessments from the United States, Canada, the United Kingdom and Australia, falling back on WHO prequalification or a Caribbean Regulatory System recommendation. CDSCO appears on none of those lists. The CRS accepts WHO-prequalified finished products directly, charges US$300 per application, and currently turns dossiers around in about 60 days. A recommendation registers nothing — it converts into a national authorisation, target 120 days, with an importer named. Every one of the 210 pharmaceutical contracts in the national tender register was awarded by National Competitive Bidding. Bidder registration requires Guyanese tax, social-security and VAT identity, so a foreign manufacturer cannot bid alone. Import licences are issued per consignment, the importer must be under a pharmacist's direct control with registered premises, and stock must arrive with at least 75% of shelf life remaining. Introduction: What an Injectable Manufacturer in Guyana Has to Prove Guyana answers this series' standing question more directly than most. Its Food and Drug Department has stated that it relies on full assessment of safety, efficacy and quality from listed reference authorities — the United States, Canada, the United Kingdom and Australia — and that where those are not met it relies on WHO prequalification or a recommendation reaching it through the Caribbean Regulatory System. India's CDSCO is on none of those lists. What makes Guyana interesting is the second half of that sentence, which most supplier pages never quote. WHO prequalification is not a consolation route here; it is a named eligibility criterion. The Caribbean Regulatory System, run as a regulatory unit inside the Caribbean Public Health Agency, explicitly accepts applications for review of finished products prequalified by WHO, alongside products approved by a regional-reference or stringent authority. For an Indian manufacturer, that is the one gate whose key can be cut in Gujarat. What Sets a World-Class Injectable Manufacturer in Guyana Apart Guyana is not a marginal user of that system — it is the anchor customer. Of roughly 353 products the CRS has recommended since 2017, Guyana has registered 164, against five in Haiti and two in the Bahamas. The Acting Director of Guyana's Food and Drug Department has said on the record that the pathway runs in parallel with national registration and has provided an efficient alternative during periods of high workload, when meeting the 120-day processing timeline may be challenging. The practical economics are modest and knowable. A CRS application costs US$300 for a manufacturer or marketing-authorisation holder, or US$150 where a local importer submits — the lower fee deliberately pushes manufacturers to file through importers. A decision is due within 90 calendar days of dossier acceptance, with a current turnaround reported at around 60, and a recommendation is valid for five years. But a recommendation registers nothing by itself: converting it into a lawful authorisation means a national application form, the CRS assessment report and certificate, the national fee, and a named importer — a target of 120 days. Quality Systems Behind Every Sterile Injectable We Ship to Guyana Guyana's door is opened by WHO prequalification or a stringent-authority approval, so the work sits in the plant. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials, and stability follows ICH Q1A with Q1B photostability. Two Guyanese requirements should be designed in rather than discovered late. Stock must arrive with at least 75% of its stated shelf life remaining, which argues for fresh manufacture against a confirmed order. And labelling must be in English — brand name, generic name, manufacturer address and the patient leaflet — with foreign-language labelling liable to seizure. Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it; we found no published Guyanese dossier-format guideline and therefore assert none. Working out whether the CRS route fits your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Guyana for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Guyana we can build the dossier and supply the WHO-format certificate of a pharmaceutical product and GMP certificate. What we cannot do is import or bid. The importer must be a Guyanese business under a pharmacist's direct control, with registered premises, holding a licence valid only for the particular importation it was issued for. We hold no Guyanese registration and recommend no distributor we have not verified. Anyone pitching Guyana on tender volume should look at how those tenders are actually let. Across the whole published award register, all 210 pharmaceutical and medical-supply awards were made by National Competitive Bidding and none by international bidding, and bidder registration requires Guyanese tax, social-security and VAT identity. Injectables are not tendered under that name either — they sit inside lotted pharmaceutical supply tenders, visible only in the lot schedules. One route needs no local agent: the regional health body's pooled funds — but they rest quality assurance on WHO prequalification and on regulators they recognise. Read Guyana's economics carefully, because the headline indicator lies. Current health expenditure was 2.47% of GDP in 2023 — down from 4.90% in 2019 — which reads like retrenchment and is the opposite. Per-capita health spending rose over the same period from about US$314 to about US$505; the ratio collapsed because oil took the denominator up more than sixfold. Population was about 836,000 in 2025, though the 2022 census counted 878,674 — about 7% above the estimate series every per-capita figure divides by. Two live items belong in any plan: Guyana is drafting new medicines legislation, so the 1971 framework is mid-replacement, and a Life Sciences Park with European backing explicitly contemplates domestic pharmaceutical and vaccine manufacturing. We print no registration fee, because none is published. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Guyana accept Indian regulatory approval for medicines? Not as a recognised approval. Guyana's Food and Drug Department has stated it relies on assessment from the United States, Canada, the United Kingdom and Australia, with WHO prequalification or a Caribbean Regulatory System recommendation as the fallback. CDSCO appears on none of those lists, and its WHO maturity-level-3 and transitional listed-authority status is scoped to vaccines, not medicines. The workable route for an Indian manufacturer is WHO prequalification or an approval from a recognised authority. Is the Indian Pharmacopoeia recognised in Guyana? This needs care, because two things are true at once. The Indian Pharmacopoeia Commission signed a memorandum of understanding with Guyana's health ministry in November 2024 recognising the Indian Pharmacopoeia as a compendium of standards. But the drug standards schedule to Guyana's Food and Drugs Act lists eight pharmacopoeias and the Indian Pharmacopoeia is not among them, and we found no amendment adding it. Treat it as recognised by memorandum, not as settled in statute. Does a Caribbean Regulatory System recommendation register my product in Guyana? No, and CARPHA is explicit about it. A recommendation is an assessment outcome member states may rely on; when a state decides to register or import, its own process still applies. In practice that means a national application form, the CRS assessment report and certificate of recommendation, payment of the national fee, and identification of an importer, with a target of 120 calendar days. Can an Indian manufacturer supply Guyana's public sector directly? Not by bidding. Every pharmaceutical award in the published tender register was made by National Competitive Bidding, and bidder registration requires Guyanese tax, social-security and VAT registration, so a foreign manufacturer needs a locally registered partner. The one channel that does not require a local agent is regional pooled procurement — which applies its own quality gate, resting on WHO prequalification. What does registration cost in Guyana, and how long does it take? We can give one figure and not the other. The Food and Drug Department's published processing timeline is 120 days, and its Acting Director has acknowledged that meeting it can be challenging under workload. On fees we found no published schedule for national registration and will not invent one. The CRS fee is published and is US$300 per medicine application, or US$150 where a local importer submits. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Top Injectable Manufacturer in Fiji – Reliable Pharmaceutical Solutions Last Updated: September 10, 2026 TL;DR: Fiji publishes exactly which foreign regulators it recognises, and India is not among them. For government supply, the regulator's own routing table says a product both registered and manufactured outside a PIC/S country is not accepted for prequalification. The open doors are WHO prequalification of the product, or a marketing authorisation from a stringent or WHO-listed authority — a solvable engineering problem, not a closed market. Key Takeaways Fiji recognises regulators that WHO designates as stringent or WHO-listed, the New Zealand regulator, and regulators of PIC/S member countries; India is in none of those categories. CDSCO does appear on WHO's maturity-level listing, but the scope recorded against it is vaccines — it is not a medicines credential for a sterile injectable. WHO-GMP certified and WHO prequalified are different things, and Fiji asks for two GMP certificates when the site sits in a country it does not recognise. Government supply and the private market are separate doors with separate rules, and prequalification is not by itself an order from the health ministry. Introduction: What an Injectable Manufacturer in Fiji Has to Prove Fiji is the most legible market this series has examined, and the legibility cuts both ways. The Medicines Regulatory Authority's prequalification guidance of March 2024 states which regulators it recognises: those WHO designates as stringent or WHO-listed authorities, the regulator of New Zealand, and the regulators of countries belonging to PIC/S, with a residual discretion to consider others case by case. India appears in none of the three named limbs, and India is not a PIC/S member. It is worth being precise about the one place India does appear, because it is easy to over-read. CDSCO is on WHO's transitional listed-authority register at maturity level 3 — but the scope recorded against it is vaccines. Every authority whose scope reads medicines and vaccines qualifies for a sterile injectable; an entry scoped to vaccines does not. Separately, the Indian Pharmacopoeia Commission signed a memorandum with Fiji's health ministry in Suva in May 2025 recognising the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is recognition of a book of standards, not of an agency, and we found no Fiji-side instrument implementing it. What Sets a World-Class Injectable Manufacturer in Fiji Apart The regulator publishes a routing matrix, and one row decides the question for most Indian exporters: a product registered in a non-PIC/S country and manufactured in a non-PIC/S country is not accepted for prequalification. That is India to India, in the Authority's own words rather than by our inference, with a shortage-based case-by-case exception as the only stated relief. A second requirement sharpens it. Where the manufacturing site sits in a country Fiji does not recognise, the guidance asks for two GMP certificates — the local one, plus one issued by a regulator Fiji does recognise — and points applicants at the European GMP database. A WHO-GMP certificate from an Indian state licensing authority satisfies the first of those and not the second. So the honest answer is that the ordinary route is closed and two specific doors are open. The first is WHO prequalification of the finished product, where the guidance makes the country of manufacture explicitly irrelevant. The second is a marketing authorisation held in a country whose regulator Fiji recognises — an EU member state, the United Kingdom, Australia, Japan, Canada, Switzerland, the United States or New Zealand — after which the Indian origin of the site stops being the deciding fact. Both are multi-year investments rather than paperwork, and a manufacturer that tells a Fijian buyer otherwise is not being straight with them. Quality Systems Behind Every Sterile Injectable We Ship to Fiji Those two doors are reachable from the same quality system, which is why the investment compounds. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic processing or terminal sterilisation, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for endotoxins and Karl Fischer for moisture in lyophilised vials. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone for a humid tropical Pacific destination rather than a temperate default. Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it, which is the format both a WHO prequalification submission and a stringent-authority filing are built from. One practical detail surprises people: Fiji expects the pack presented to it to be identical to the pack approved in the reference market. The instinct to design a Fiji-specific carton is wrong, and rebuilding artwork late is a common cause of avoidable delay. Working out which door into Fiji fits your product? Talk to our regulatory team about prequalification dossiers, reference-market strategy and pack-identity requirements. Why Farbe Firma is the Trusted Injectable Manufacturer in Fiji for Global Buyers Fiji has two doors, not one, and conflating them causes most of the confusion we see. For government supply, an overseas supplier may apply to the Authority directly; the manufacturer and the product are prequalified separately, and goods imported by Fiji Pharmaceutical and Biomedical Services against a prequalification are exempt from per-shipment import permits. For the private market, the applicant is a locally registered and licensed Fijian entity, which lists the product and holds the import permit — and that listing is applicant-specific and not transferable without the Board's approval, a real commercial lock-in worth weighing when a distributor is chosen. We would add that the evidentiary requirements published in the prequalification guidance are written for prequalification, and a manufacturer should confirm with the Board what applies to a private-market listing rather than reading one across to the other. The buyer is also not always the ministry. For HIV and tuberculosis commodities the operative purchaser under a health-procurement project signed in July 2024 is UNDP, applying the Global Fund's quality-assurance policy, which accepts WHO prequalification, a stringent authority, a WHO-listed authority, or expert-review-panel review. UNFPA's Pacific presence is based in Fiji, with the national warehouse acting as a node for several countries. These donor rules are frequently the gate that actually binds, and they point at the same two doors as the national regulator: solving for WHO prequalification solves for several buyers at once. The market itself is modest. The population stood at 928,784 in 2024, current health expenditure at 3.62% of GDP in 2023, with 8.31% paid out of pocket and 11.64% financed externally, all on WHO Global Health Expenditure Database figures. We would caution against reading trends into that series: a 2021 spike reflects a pandemic-era GDP denominator, and a later movement in the out-of-pocket share reflects a methodology change. On costs and timelines we print nothing: no fee schedule and no statutory processing time appears in the Act, the regulations or any of the guidance documents we read. One further correction, because it circulates widely: the twelve-month shelf-life-on-arrival rule often quoted here is India's import rule, not Fiji's, and we found no Fijian equivalent. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Fiji accept Indian regulatory approval for medicines? Not as a recognised approval. Fiji recognises WHO-designated stringent and WHO-listed authorities, the New Zealand regulator, and regulators of PIC/S member countries, and India falls into none of those. The Authority's own routing table records that a product registered and manufactured in a non-PIC/S country is not accepted for prequalification, with a shortage-based exception decided case by case. Is WHO-GMP certification enough to supply Fiji? No, and the distinction matters. WHO-GMP certification is a GMP credential issued by an Indian licensing authority; WHO prequalification is an assessment of a specific product by WHO. Where the site is in a non-recognised country, Fiji's guidance asks for a second GMP certificate issued by a regulator it does recognise, which a WHO-GMP certificate does not supply. Does the Indian Pharmacopoeia memorandum open a registration pathway in Fiji? No. The memorandum signed in Suva in May 2025 recognises the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is a book of quality standards, not an agency recognition, and waives no registration requirement. We found no Fiji-side implementing instrument, and the Authority's guidance still names the British, European, International and United States pharmacopoeias. Does a foreign manufacturer need a local agent in Fiji? It depends on the door. For government supply an overseas supplier may apply for prequalification directly. For the private market the applicant must be a locally registered and licensed Fijian entity, which then owns the listing and holds the import permit — so a blanket claim that a local agent is always legally required would be wrong, and so would the opposite. What do registration and prequalification cost in Fiji, and how long do they take? We will not print a figure for either. No fee schedule and no statutory timeline appears in the Medicinal Products Act, its regulations, or any of the Authority's guidance documents we were able to read. Both should be confirmed with the Authority directly, and any plan that depends on a date should be built after that confirmation. Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: info@farbefirma.com | Request a Quote / View Products / FAQ / Blog

Last Updated: September 3, 2026 TL;DR: The Gambia answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three lists at three layers, and India appears on none of them by name. The Medicines Control Agency's 2023 reliance policy names the EMA, the EU and EEA authorities, the MHRA, the US FDA, PMDA, Swissmedic, Health Canada, the TGA, WHO prequalification, AVAREF, ECOWAS and PIC/S, plus any authority the WHO has benchmarked at maturity level 3 or above; India's CDSCO holds that level for vaccines only, so a small-molecule injectable cannot use it. The 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries, from Australia to the United States, without India. The practical consequence is a full 180-day review rather than the 90-day abridged one, a local representative and a Gambia-resident pharmacovigilance person, and — uniquely for Indian exporters — a pre-shipment inspection and analysis certificate on every consignment. Out-of-pocket spending is a third of health expenditure and the public buyer is Central Medical Stores; on the MCA register roughly six in ten products are already made in India, which tells you the route works when it is walked properly. Key Takeaways Three lists, none with India. The MCA Reliance Policy of November 2023 lists recognised institutions by name and adds a general clause for authorities at WHO maturity level 3 or higher; CDSCO is benchmarked at level 3 for vaccines only. The June 2025 reliance guideline relies on the WHO-Listed Authorities list, AVAREF, ECOWAS/WAHO and WHO prequalification. The June 2026 listing guideline names forty stringent-authority countries; India is not among them. An Indian WHO-GMP injectable without an SRA authorisation or WHO prequalification takes the standard 180-day route. The registration mechanics are written down and workable. Applications go in the MCA CTD format, with WAHO, WHO, EU or ICH CTD variants accepted, in English, with one hard copy of Module 1 and the rest on USB, three commercial-pack samples with batch certificates of analysis, a manufacturing licence and GMP certificate, and evidence that the product is registered and marketed in its country of origin. A non-resident holder must appoint a local representative registered in The Gambia and a pharmacovigilance person resident there. The authorisation lasts five years and may be renewed once for three. India is singled out at the border. Since June 2023 every pharmaceutical consignment from India has needed a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, with document review, physical inspection at loading, sampling and testing at an MCA-approved laboratory, a 90-day certificate validity and at least 60% shelf life remaining on arrival. We could not confirm how the regime is being enforced in 2026; a supplier should plan for it in full. The commercial gate is the State and the programmes. Current health expenditure was about USD 26 per person and 2.9% of GDP in 2023, out-of-pocket payments were 33.8% of it, Central Medical Stores procures for the public facilities through the GPPA portal, and Global Fund grants for malaria, HIV and TB run to 2026 and 2027. The National Health Insurance Scheme has expanded from 13 to 69 contracted facilities; its medicines benefit has not been published in a form we could read. Introduction: Why The Gambia Demands a Premium Injectable Manufacturer in The Gambia Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? The Gambia is the first market where the honest answer is three lists at three layers, each of which we read. The first is the Medicines Control Agency's Reliance Policy, version 3 of 15 November 2023, whose appendix of recognised institutions names the European Medicines Agency, the national authorities of the EU and EEA states, the MHRA, the US FDA, Japan's PMDA, Swissmedic, Health Canada, Australia's TGA, WHO prequalification, AVAREF, the ECOWAS and WAHO harmonisation programme and PIC/S, and then adds a general clause for any national authority the WHO has benchmarked at maturity level 3 or above. That clause is the only door through which India could enter, and on the WHO's August 2026 list CDSCO holds maturity level 3 for vaccines only. For a sterile small-molecule injectable the door is closed. The second layer is the Reliance Guideline MCA-GL-109, version 2 of 25 June 2025, with its annex of reference institutions: the WHO-Listed Authorities and the transitional list, AVAREF, the ECOWAS and WAHO regional mechanism and WHO prequalification, with partial reliance allowed for an active ingredient on the strength of a WHO certificate, a WHO prequalification confirmation or an EDQM certificate of suitability. The guideline also states that reliance on a decision which was itself based on reliance is not acceptable, which closes the indirect route through a third country. The third layer is the Listing Guideline MCA-GL-117 of 19 June 2026, made under the 2023 amendment to section 26 of the Medicines and Related Products Act, which names forty countries considered to have stringent regulatory authorities — Australia, the twenty-seven EU members, Iceland, Liechtenstein, Norway, Japan, Saudi Arabia, South Korea, Russia, Singapore, Switzerland, Turkey, the United Kingdom and the United States — and allows their approved products to be listed for import in ten working days without registration. India is not on it. What this means for a buyer is simple: a premium injectable manufacturer in The Gambia is one that registers the ordinary way, completely and on the first attempt. What Sets a World-Class Injectable Manufacturer in The Gambia Apart Start with the dossier, because the MCA has written it down more clearly than most agencies in the region. Registration Guideline MCA-GL-102, version 4, calls for the MCA common technical document and states that WAHO, WHO, EU and ICH CTD formats are accepted; a generic files Modules 1, 2 and 3 with the bioequivalence section of Module 5 where relevant, on application form MCA-F-112/01, with one hard copy of Module 1 and a complete electronic copy on USB. The language is English, with notarised translations of anything else. Three samples in commercial packs go in with signed batch certificates of analysis. The Module 1 checklist asks for evidence that the product is registered in its country of origin and a certificate from the competent authority there that it is marketed, with a WHO-format certificate of a pharmaceutical product listed among the certification documents as applicable; a manufacturing licence and a GMP certificate are mandatory for an imported product, and the agency reserves the right to inspect the site at a fee. The 2022 fees regulations, which we read from a scanned gazette and therefore quote with care, put registration of an imported medicine at USD 300, renewal at USD 300, and a GMP inspection outside West Africa at USD 7,000. The clock is statutory and realistic. The agency acknowledges an application within two weeks, the standard review is 180 days and the abridged review for products with a stringent-authority authorisation or WHO prequalification is 90 days, with the clock stopping while queries are outstanding. A marketing authorisation is valid for five years and, under section 30 of the Act, may be renewed once for three years, after which a fresh application is required; the renewal must be filed at least 90 days before expiry and a late renewal is treated as a new application. Two structural requirements shape the commercial arrangement. A holder that is not resident in The Gambia must appoint a local representative that is a legal entity registered there, although the agency may accept a regional representative resident elsewhere in West Africa, and appointing one does not relieve the holder of legal responsibility. And the holder must have a qualified person for pharmacovigilance resident in The Gambia and file a summary of its pharmacovigilance system. We did not read the Act itself, which exists online only as page images, nor the 2020 regulations, so every requirement above is as the MCA's own guidelines quote it. Quality Systems Behind Every Injectable Supplied to The Gambia For a sterile injectable the evidence the MCA will look for is the evidence any inspector expects: media-fill records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and HPLC or GC assay and impurity methods validated to ICH standards, with ICH Q1A stability data generated for the hot and humid zone rather than extrapolated. Because the GMP certificate is mandatory and India is not a recognised authority under the reliance policy, the certificate carries less weight than the file behind it, and a supplier should have the site master file and the last inspection report ready for the day the MCA exercises its right to visit. The requirement that is unique to Indian suppliers deserves its own paragraph. Guidance MCA-G-113/04 of 15 June 2023, issued after the 2022 contaminated-syrup deaths, requires every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai. The exporter registers with the inspection body for a fee of INR 20,000, each shipment goes through a document check that includes the state licensing authority's product permission, the MCA registration certificate and a valid certificate of pharmaceutical product, a physical inspection at loading, and sampling and testing at an MCA-approved laboratory; injectables are analysed within about fifteen days, the certificate is valid for ninety days and the product must have at least sixty per cent of its shelf life remaining on arrival. The guidance is still listed on the agency's website; we could not establish how strictly it is applied in 2026 or what the per-shipment cost now is, and we will not guess. Plan for it in full and build the lead time into the supply contract. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in The Gambia for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we can present them in the MCA CTD layout the agency asks for, with the Module 1 certification pack — manufacturing licence, GMP certificate, WHO-format CPP, evidence of registration and marketing in India — assembled so that a 180-day review has nothing to send back. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written to the standard a site inspection would test, and we are candid that no reliance shortcut is available to an Indian product in The Gambia without WHO prequalification. We also treat the pre-shipment regime as part of the delivery, not an obstacle to it. The bilateral relationship is substantial and the pharmaceutical trade is established. India's Ministry of External Affairs brief records bilateral trade of USD 175.79 million in 2022–23, with Indian exports of USD 122.60 million, and lists drugs and pharmaceuticals among the major export items without ranking them; a joint commission agreement was signed in November 2021, and we found no health or pharmaceutical memorandum and no cooperation agreement between CDSCO and the MCA. UN Comtrade puts India-reported exports of pharmaceutical products to The Gambia at USD 8.66 million in 2022, USD 6.41 million in 2023, USD 9.46 million in 2024 and USD 8.81 million in 2025, while The Gambia reports imports from India of USD 3.62 million, USD 2.23 million and USD 3.07 million for 2022 to 2024; the two series differ by a factor of two to three and we give both rather than an average. The MCA's own register, updated in August 2026, carries about 2,500 products, and on a keyword count roughly six in ten are manufactured in India — a fact that says the route works, and that the competition on it is Indian. Where the money is: The Gambia has 2.82 million people, gross national income per capita of USD 930 in 2025, current health expenditure of about USD 26 per person and 2.9% of GDP in 2023, and life expectancy of 66.1 years. Out-of-pocket payments were 33.8% of health expenditure in 2023, so the State and its partners are the larger buyer. The Directorate of National Pharmaceutical Services and Central Medical Stores procure and distribute for the public facilities, with tenders run under the Public Procurement Act 2022 on the GPPA portal, and the Global Fund's active grants — malaria to June 2027, HIV and TB to December 2026 — bring pooled procurement into the same warehouses. The National Health Insurance Scheme, created by the 2021 Act, expanded its contracted facilities from 13 to 69 in 2025 and is seeking mandatory contributions in 2026; its medicines benefit and any reimbursement list are not published in a form we could read. Tuberculosis incidence is 138 per 100,000, and the demand for sterile injectables is the general hospital formulary — antibiotics, anaesthetics, emergency and maternal-health medicines — rather than a single programme. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on The Gambia's list of recognised regulatory authorities? Not by name on any of the three lists. The Reliance Policy of November 2023 names the EMA, EU and EEA authorities, MHRA, US FDA, PMDA, Swissmedic, Health Canada, TGA, WHO prequalification, AVAREF, ECOWAS/WAHO and PIC/S, plus any authority at WHO maturity level 3 or above; CDSCO holds that level for vaccines only. The June 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries without India. An Indian product therefore uses the standard 180-day registration route. What does a Gambian registration application require? Under Registration Guideline MCA-GL-102: an MCA-format CTD, or a WAHO, WHO, EU or ICH CTD, in English, with one hard copy of Module 1 and the full dossier on USB; three commercial-pack samples with batch certificates of analysis; a manufacturing licence and GMP certificate; evidence of registration and marketing in the country of origin with a WHO-format CPP as applicable; a local representative registered in The Gambia for a non-resident holder; and a Gambia-resident pharmacovigilance person. The 2022 fees regulations put registration of an imported medicine at USD 300. How long does registration take and how long is it valid? The MCA acknowledges within two weeks, reviews a standard application within 180 days and an abridged one within 90 days, with the clock stopping on queries. The authorisation is valid for five years and can be renewed once for three years, after which a fresh application is needed; renewal must be filed at least 90 days before expiry. What is the pre-shipment inspection requirement for Indian medicines? Since June 2023, guidance MCA-G-113/04 has required every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, covering a document check, physical inspection at loading, and sampling and testing at an MCA-approved laboratory. Injectables are analysed in about fifteen days, the certificate is valid for ninety days and the product must arrive with at least 60% shelf life. We could not verify how it is enforced in 2026; plan for it in full. How do we sell to the public sector in The Gambia? Through Central Medical Stores and the Directorate of National Pharmaceutical Services, which procure for public facilities under the Public Procurement Act 2022 via the GPPA portal, and through the Global Fund programmes for malaria, HIV and TB whose grants run to 2026 and 2027. Registration with the MCA comes first, and a local importer holding MCA importer and warehouse licences is the practical partner. The National Health Insurance Scheme is expanding but its medicines benefit was not published in a form we could read. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 11, 2026 TL;DR: The Comorian rulebook is eight days old. On 3 September 2026 ANAMEV published, for the first time in one place, eleven CTD dossier checklists, the marketing-authorisation form and five governing decisions. A decision is due within 90 days — but the clock starts when fees are paid, and the fee schedule is published nowhere. The commercial route is narrower still: the national list of licensed wholesalers has exactly one entry. Key Takeaways ANAMEV published its complete marketing-authorisation requirements on 3 September 2026. Any guidance on Comorian registration written before that date describes a different regime. Décision N°012 adopts mutual recognition and the WHO Collaborative Registration Procedure — then names no authority at all, and CDSCO appears nowhere. WHO prequalification of the active ingredient is the one mechanism that measurably shortens the dossier. OCOPHARMA is the only licensed wholesaler in the country, serving 25 licensed pharmacies across three islands. Representing your products requires a pharmacien-conseil resident in the Comoros who is jointly liable alongside you. Today the control that actually binds is customs, not registration: a per-consignment import licence cleared in four working days, then physical inspection that names injectable medicines as its own category. Introduction: What an Injectable Manufacturer in Comoros Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? The Union of the Comoros answers in a way no earlier market has, because its answer is eight days old. On 3 September 2026 the Agence Nationale des Médicaments et des Évacuations Sanitaires published eleven CTD dossier checklists, the marketing-authorisation form and five governing décisions. Before that, the regime existed only on paper under the 2020 Code de la Santé Publique. Read what it says rather than what it suggests. Article 10 of Décision N°012 adopts the principle of mutual recognition and implements the WHO Collaborative Registration Procedure — and then names no authority. There is no reliance list and no mention of CDSCO anywhere in ANAMEV's published set. What is named is narrower and more useful to a manufacturer: a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, a WHO-format GMP certificate, bioequivalence data, and a French-language summary of product characteristics on the WHO model. The only pharmacopoeia named anywhere is the European one. What Sets a World-Class Injectable Manufacturer in Comoros Apart The one place the new rulebook offers genuine leverage is WHO prequalification. Where the active ingredient is WHO-prequalified, parts of Module III fall away: container-closure data is not required, and manufacturing information is required only where finished-product sterility depends on the active ingredient. That is the closest thing to an abridged pathway in the Comorian system, and it is earned in a laboratory rather than negotiated in a meeting. Against that sits an arithmetic problem worth stating plainly. Article 11 gives ANAMEV a maximum of 90 days to grant or refuse a new authorisation — but the clock starts on the date the fees are paid, and we could find no published fee schedule to pay against. The file must also pass the Commission Nationale d'Homologation des Produits Pharmaceutiques and a technical expert committee, each of which ordinarily meets once a quarter. A 90-day maximum gated behind two quarterly calendars is a planning constraint, and a supplier who offers a firm date should be asked how they arrived at it. Quality Systems Behind Every Sterile Injectable We Ship to Comoros The dossier ANAMEV now asks for is largely the dossier a serious sterile plant already generates. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability, on the climatic zone an equatorial island destination actually requires. Two Comoros-specific details change how the file is assembled. The summary of product characteristics must be in French and follow the WHO model — a translation workstream to be scheduled, not an afterthought at submission. And the generic route requires bioequivalence or comparative dissolution data as a matter of course. Dossiers are built in CTD structure, with ACTD available where a regulator prefers it; we found no Comorian requirement for eCTD and therefore claim none. Working out whether Comoros is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Comoros for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Comoros we can build the CTD dossier, supply the WHO-format CPP and GMP certificate, generate bioequivalence and stability data, and prepare the French RCP. What we cannot do is import. ANAMEV's published list of licensed wholesalers contains exactly one entry — the state-owned OCOPHARMA in Moroni — against 25 licensed pharmacies in the whole country. We hold no Comorian registration and recommend no partner we have not verified. Representation is regulated separately and more heavily than most exporters expect. Under Décision N°007, a medical promotion or representation agency must retain a pharmacien-conseil who resides in the Comoros and is registered with the Ordre National des Pharmaciens, and that pharmacien-conseil is jointly liable, criminally included, alongside the agency. The commercial gate is tighter than the technical one. And for the malaria, HIV and tuberculosis volumes that dominate donor spending, a second gate sits above both: the Global Fund's quality-assurance policy accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority, or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it at maturity level 3 for vaccines only. The numbers are small and the honesty about them matters more than the size. Population was 866,628 in 2024 on World Bank figures; current health expenditure was 6.55% of GDP in 2023, with 56.57% paid out of pocket and 26.77% financed externally, on WHO Global Health Expenditure Database data. That external share was 43.30% a year earlier — households, not donors, absorbed the swing. We will not print a market-size figure: the two mirror-trade sources we found differ by roughly five times. Nor will we print a registration fee, because none is published. One caveat we would rather state than hide: OCOPHARMA's own quality lead listed non-registration among the system's live gaps in 2024, and WHO's 2024–2028 country strategy records essential-medicine availability at 28%. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Comoros recognise India's CDSCO or Indian regulatory approval? We found no Comorian instrument naming CDSCO, and no published list of recognised foreign regulators. Décision N°012 adopts mutual recognition as a principle and implements the WHO Collaborative Registration Procedure, but names no authority to recognise. What ANAMEV does require is a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, plus a WHO-format GMP certificate — requirements about document format, not about which agency issued the approval. Is the Indian Pharmacopoeia accepted in Comoros? Not as far as any published document shows. The only pharmacopoeia named in ANAMEV's dossier requirements is the European Pharmacopoeia, through a certificate of suitability. Specifying to an Indian Pharmacopoeia monograph is not prohibited and may be entirely appropriate for the molecule — but nothing in the Comorian rulebook gives it recognised status, and a supplier claiming otherwise is reading something that is not there. Does a foreign manufacturer need a local partner in Comoros? Effectively yes, on two counts. Importing requires an establishment registered with ANAMEV holding a one-year import approval, and ANAMEV's published wholesaler list has a single entry. Separately, promoting or representing your products requires a ministerially authorised agency retaining a pharmacien-conseil resident in the Comoros and registered with the Ordre National des Pharmaciens, who carries joint liability. Neither route lets an overseas manufacturer act alone. What does registration cost in Comoros, and how long does it take? We will print a timeline and not a cost. Décision N°012 sets a maximum of 90 days for a decision on a new application and on a renewal, with renewals filed at least three months before expiry. But the 90 days run from the date fees are paid, and we could find no published fee schedule — the amounts are set by decisions of ANAMEV's Director-General that are not on the public record. Confirm both with ANAMEV directly. What actually controls an injectable consignment arriving in Comoros today? Customs, in practice. Every import needs a prior ANAMEV licence requested through the SYDONIAWorld system, with a published processing time of four working days and a fee of 10,000 KMF. On arrival a separate release authorisation applies: documentary inspection within 48 working hours, then physical inspection at the port or airport, under procedures that name injectable medicines as their own inspection category. Thermolabile and biological products can move under a provisional release. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 31, 2026 TL;DR: Puerto Rico is not a sovereign regulatory jurisdiction, and almost everything written about supplying it gets that half-right in a way that costs money. There is no Puerto Rican marketing authorisation to win: medicines are approved by the US FDA under the Federal Food, Drug, and Cosmetic Act, whose definition of “State” includes the Commonwealth, so the entry ticket is an ANDA or 505(b)(2) plus an FDA-inspected plant. But it is equally wrong to conclude that nothing local applies. Reglamento 156B, made under the Ley de Farmacia de Puerto Rico, forbids displaying, offering, distributing, selling, delivering, storing, donating or promoting any medicine on the island unless it is registered with the Department of Health, at USD 25 per registration transaction, and that registration can only be made by a licensed manufacturer or distributor or a certified resident representative agent. The commercial reality behind both facts is starker still: Puerto Rico exported USD 48.3 billion of pharmaceuticals in FY2024 to a population of about 3.18 million and falling. It is a competitor before it is a customer. This guide sets out what is verified, what we could not read, and where the real opportunity for an Indian sterile injectable maker actually sits. Key Takeaways There is no Puerto Rican drug approval to obtain. Product authorisation is US FDA under the FD&C Act — ANDA under section 505(j), 505(b)(2), NDA or BLA, with a Type II DMF for the API, establishment registration and drug listing under section 510, and a mandatory US agent under 21 CFR 207.69(b) who must reside or keep a place of business in the United States. FDA has no GMP mutual-recognition arrangement with India; the only pharmaceutical MRA of that kind is with the European Union. WHO-GMP certification and CDSCO approval carry no recognition weight with FDA, so every site must be inspected by FDA itself, and FDA has extended unannounced foreign inspections building on a pilot run in India and China. But FDA approval alone is not enough to sell there, and this is the error that costs money. Article 3.01 of Reglamento 156B, made under Ley 247-2004, prohibits any person in Puerto Rico from displaying, offering for sale, distributing, selling, delivering, storing, giving away or promoting any medication, prescription or over-the-counter, unless it has been registered with the Department of Health. The fee is USD 25 per registration transaction or change. Establishment licences run to USD 1,500 for pharmaceutical industry, USD 500 for a non-prescription wholesale distributor and USD 250 for biological products. Registration is administered by the División de Medicamentos y Farmacias. Confirm the schedule before budgeting: the regulation dates from 2020 and we could not verify that the fees are unchanged in 2026. The structural cost gap is written into United States statute and it is permanent. The GDUFA fee notices for both FY2026 and FY2027 apply a USD 15,000 surcharge to facilities located outside “the United States and its territories and possessions”. Puerto Rico is inside that perimeter, so a plant on the island pays the domestic rate while a plant in Gujarat pays the foreign one. For FY2027, effective 1 October 2026, a foreign finished-dosage facility pays USD 245,033, a foreign API facility USD 54,680, a foreign contract manufacturing facility USD 70,208, an ANDA filing USD 375,684 and a Type II DMF USD 109,899. Being inside the United States customs territory has the same consequence for trade: there is no India–Puerto Rico trade line, no separate tariff and no separate import licence. The honest strategic reading is that Puerto Rico is a competitor first. Government figures put pharmaceutical exports at USD 48,328 million in FY2024, seventy-four per cent of the island’s total exports, produced by 13,197 people across 60 establishments and more than fifty FDA-approved plants, against a resident population the Census Bureau estimated at 3,184,835 on 1 July 2025 and falling. The opening for an Indian sterile injectable maker is not market entry but United States supply resilience: when Hurricane Maria disabled Baxter’s island capacity in 2017 and worsened a national intravenous fluid shortage, FDA opened the door to foreign sterile supply. That concentration risk has not gone away. Introduction: Why Puerto Rico Demands a Premium Injectable Manufacturer in Puerto Rico Puerto Rico is the most misunderstood entry on any pharmaceutical export map, and the misunderstanding runs in both directions. It is an unincorporated territory of the United States, inside the United States customs territory, and the Federal Food, Drug, and Cosmetic Act defines “State” to include the Commonwealth of Puerto Rico. The consequence is immediate and non-negotiable: there is no Puerto Rican dossier to compile, no local efficacy review, no island marketing authorisation, and no Common Technical Document filed in San Juan. A supplier who arrives looking for the Puerto Rican equivalent of a national medicines agency will not find one, because it does not exist. Any content that describes a Puerto Rican drug registration procedure with dossier modules and review timelines is describing something imaginary, and we would rather say so plainly than reproduce it. The product pathway is the ordinary United States one, and it is demanding on its own terms: an abbreviated new drug application under section 505(j), or a 505(b)(2) or full new drug application where the product warrants it, supported by a Type II drug master file for the active ingredient, establishment registration and drug listing under section 510, and a designated United States agent under 21 CFR 207.69(b) who must reside or maintain a place of business in the United States and cannot be a mailbox or an answering service. The opposite error is the more expensive one, and it is the reason this article exists in the form it does. It does not follow from federal jurisdiction that nothing local applies. Reglamento 156B, an amendment to Reglamento 156 made under Ley 247-2004, the Ley de Farmacia de Puerto Rico, imposes a genuine island-level regime on top of FDA approval, and its article 3.01 is expressed as a prohibition rather than a formality: no person in Puerto Rico may display, offer for sale, distribute, sell, deliver, store, give away or donate, or promote in any way, any medication for use in humans or animals unless that medication has been registered with the Department. Note that storage is in the list. The fee is modest, USD 25 for each registration transaction or change to registered information, and the administering body is the División de Medicamentos y Farmacias within the Secretaría Auxiliar para la Regulación de la Salud Pública, which also handles establishment licensing, certificates of origin, free-sale certificates and good manufacturing practice matters. Two things separate this from an administrative detail: registration may only be performed by a duly licensed manufacturer or distributor, or delegated after notice to a certified resident representative agent, and the Department maintains a distinct process for non-resident distributors that we will come to, because what we could not read about it matters as much as what we could. What Sets a World-Class Injectable Manufacturer in Puerto Rico Apart The first thing that separates a serious supplier here is understanding that Indian regulatory credentials buy nothing at the federal door. The United States Food and Drug Administration operates one pharmaceutical good manufacturing practice mutual-recognition arrangement of consequence, and it is with the European Union: the sectoral annex entered into force on 1 November 2017 and capability assessments for all European Union human-drug authorities were completed on 11 July 2019, with further arrangements covering Switzerland and the United Kingdom. No Indian authority appears anywhere in that framework. WHO-GMP certification, CDSCO approval and Indian Schedule M compliance therefore carry precisely zero recognition weight with FDA, and every site intended to supply the United States market, Puerto Rico included, must be inspected by FDA itself. FDA has moreover announced an expanded use of unannounced inspections at foreign manufacturing facilities, building explicitly on a foreign unannounced inspection pilot conducted in India and China, which means an Indian plant should treat the unannounced inspection as the base case rather than the exception. A quality system that is genuinely inspection-ready on any working day, rather than one that is assembled in the fortnight before a scheduled visit, is the difference between a viable United States programme and a costly one. The second differentiator is arithmetic, and it is uncomfortable. The generic drug user fee structure surcharges foreign facilities by statute. Both the FY2026 and the FY2027 Federal Register notices set the differential for facilities located outside “the United States and its territories and possessions” at USD 15,000, and because Puerto Rico sits inside that perimeter a plant on the island pays the domestic rate while a plant in Gujarat does not. In FY2026, in force until 30 September 2026, an ANDA filing costs USD 358,247, a Type II drug master file USD 102,584, a foreign finished-dosage facility USD 253,943, a foreign active ingredient facility USD 58,549 and a foreign contract manufacturing facility USD 72,346. From 1 October 2026 the FY2027 rates apply: ANDA USD 375,684, drug master file USD 109,899, foreign finished-dosage facility USD 245,033, foreign active ingredient facility USD 54,680, foreign contract manufacturing facility USD 70,208. Programme fees run from USD 192,729 for a small business to USD 1,927,291 for a large operation in FY2027. None of this is negotiable and none of it is temporary, so it belongs in the business case at the outset rather than as a surprise in year one. The third differentiator is supply-chain data: the Drug Supply Chain Security Act is federal and applies in Puerto Rico exactly as in any state, with no territorial carve-out, and a foreign manufacturer is already fully in scope, so serialised package-level data and interoperable electronic transaction records must flow to the United States importer from the first shipment. Quality Systems Behind Every Injectable Supplied to Puerto Rico On the island-level requirements we want to be exact about the boundary between what we verified and what we could not, because this is where a confident-sounding answer would be worth less than an honest one. What is verified is the prohibition in article 3.01, the USD 25 registration fee at article 3.04(h), the rule that registration is performed by a licensed manufacturer or distributor or by a certified resident representative agent, and the establishment licence fees at article 2.03. What we could not establish is the single most important operational question for a foreign manufacturer: whether you must yourself hold a Puerto Rico licence, or whether the obligation rests wholly on your licensed local distributor. Article 3.01 attaches the duty to persons in Puerto Rico and article 3.04 says registration will be performed by duly licensed manufacturers or distributors, which reads naturally as putting the filing in your distributor's hands. But the Department publishes notices addressed specifically to non-resident distributors, in both Spanish and English, and those documents are image-only scans with no machine-readable text. We could not read them. They are exactly where this question would be resolved, and we will not guess at their contents. Settle it directly with the División de Medicamentos y Farmacias or with Puerto Rico counsel before you commit to a structure. A second open point compounds the first. The Department has issued an administrative order extending a moratorium on licences for representative agents of manufacturers or distributors of medications. We did not open that order and cannot confirm whether the moratorium remains in force in 2026. If it does, it may close off the very delegation route that article 3.04 otherwise contemplates, forcing reliance on an already-licensed distributor rather than on an agent appointed for the purpose. That is a structural question with commercial consequences and it should be asked before a distribution agreement is signed, not after. For controlled substances, federal Drug Enforcement Administration registration applies and Puerto Rico separately enforces its own controlled substances law of 1971, though for a general sterile injectable portfolio this is usually out of scope. We should also be candid about what this article does not contain: we researched no Puerto Rican disease-burden data at all. There is no diabetes, chronic kidney disease, dialysis or oncology figure here, no hospital or bed count, and no health expenditure number, because none was obtained. Assertions about the island’s clinical demand profile are common in supplier content and we are not going to add to them without a source. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Puerto Rico for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and supplying more than thirty export markets. We work across dry powder and liquid vials, ampoules and lyophilised presentations, with analytical control built on HPLC, GC, Karl Fischer titration and LAL bacterial endotoxin testing, and stability programmes designed to ICH Q1A and Q1B. We prepare documentation in CTD, ACTD and eCTD formats according to what the destination authority actually asks for, and we maintain drug master files where a market requires them. For a United States programme, including Puerto Rico, we are clear-eyed that this portfolio is a starting point and not a passport: it is the platform on which an FDA submission and an FDA inspection are built, not a substitute for either. What we bring to a Puerto Rico conversation is a refusal to sell the easy version of it. A partner who tells you that FDA approval is all you need has not read Reglamento 156B; a partner who offers to walk you through Puerto Rican dossier submission has invented a procedure that does not exist. We would rather set out the two-layer structure accurately, name the fee schedule with the caveat that it dates from 2020, tell you which documents we could not read, and let you take advice on the points that turn on them. That approach has a practical payoff as well as an ethical one, because the questions we are flagging — whether the foreign manufacturer needs its own licence, and whether the representative agent moratorium still bites — are precisely the ones that determine whether your route to the island runs through an agent or through a distributor, and that decision is expensive to reverse. The larger strategic point is the one we would put to any buyer considering this market, and it reframes the question. Puerto Rico produced USD 48,328 million of pharmaceutical exports in fiscal year 2024, seventy-four per cent of everything the island exports, from 60 establishments employing 13,197 people, with pharmaceutical manufacturing contributing roughly thirty per cent of gross domestic product and more than fifty FDA-approved plants on the island. The resident population was estimated at 3,184,835 on 1 July 2025, down about ninety-seven thousand since the 2020 census. Three million people cannot absorb forty-eight billion dollars of output; the island is an export platform aimed at the United States mainland, which is the same customer an Indian exporter is aiming at. The island does import, and substantially — USD 16,805 million in FY2024, of which USD 6,503 million came from foreign countries, led by Ireland, Singapore, Portugal and Italy, with India inside the residual category. But the sharper opportunity is resilience. When Hurricane Maria took out power at Baxter’s Puerto Rico plants in September 2017 and materially worsened a national shortage of intravenous saline and amino acid injections, FDA responded by not objecting to temporary imports from Ireland, Australia, Mexico, Canada and Germany and by clearing additional suppliers. That is the best-documented precedent for FDA using regulatory discretion to admit foreign sterile injectable supply during a United States shortage, and the concentration of sterile injectable and biologic capacity on a hurricane-exposed island has not changed since. An ANDA portfolio in shortage-listed sterile injectables, filed and inspected in advance, is a more realistic plan than a Puerto Rico market-entry strategy. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Do I need a separate Puerto Rico drug registration, or is FDA approval enough? Both, and this catches people out. There is no Puerto Rican marketing authorisation — product approval is US FDA under the Federal Food, Drug, and Cosmetic Act, which defines “State” to include the Commonwealth. But article 3.01 of Reglamento 156B, made under Ley 247-2004, separately prohibits displaying, offering for sale, distributing, selling, delivering, storing, giving away or promoting any medication in Puerto Rico unless it has been registered with the Department of Health, at USD 25 per registration transaction. FDA approval is necessary but not sufficient. The two are different things: FDA decides whether the drug may be marketed, the Department of Health decides whether it may be sold on the island. Must an Indian manufacturer itself hold a Puerto Rico licence? We do not know, and we would rather say so than guess. Article 3.01 attaches the duty to persons in Puerto Rico and article 3.04 provides that registration is performed by duly licensed manufacturers or distributors, or by a certified resident representative agent, which reads naturally as placing the filing with your licensed local distributor. But the Department publishes notices addressed specifically to non-resident distributors, in Spanish and English, and both are image-only scans that we could not read. That is precisely where this would be settled. There is also an administrative order extending a moratorium on representative agent licences whose current force we could not confirm, and which may close the delegation route. Take this to the División de Medicamentos y Farmacias or to Puerto Rico counsel before choosing a structure. Does our WHO-GMP certificate help with FDA? No. FDA operates one pharmaceutical GMP mutual-recognition arrangement of this kind and it is with the European Union, in force from 1 November 2017 with capability assessments for all European Union human-drug authorities completed on 11 July 2019, plus arrangements with Switzerland and the United Kingdom. No Indian authority appears in that framework. WHO-GMP certification and CDSCO approval carry no recognition weight with FDA, and every site must be inspected by FDA itself. FDA has also expanded unannounced foreign inspections, building on a pilot conducted in India and China, so an Indian site should plan for inspection readiness as a standing condition rather than an event. Is there a separate India to Puerto Rico trade route or tariff? No, and this follows from the same fact that drives the fee position. Puerto Rico is inside the United States customs territory, so goods arriving from India are United States imports clearing under the harmonised tariff schedule. There is no bilateral India–Puerto Rico trade line, no separate tariff schedule and no separate import licence. The island does publish its own external trade statistics as a distinct series, which recorded USD 16,805 million of pharmaceutical imports in FY2024 including USD 6,503 million from foreign countries, but India is not broken out within them and we did not query United Nations Comtrade or Indian trade databases for this article, so we are not offering an India-to-Puerto Rico figure. What is the realistic commercial opportunity for an Indian injectable maker? United States supply resilience rather than island market entry. Puerto Rico exported USD 48,328 million of pharmaceuticals in FY2024, seventy-four per cent of its total exports, from 60 establishments and 13,197 employees, to a resident population estimated at 3,184,835 in July 2025 and declining. It is an export platform competing for the same mainland customer you are. The instructive precedent is 2017, when Hurricane Maria disabled Baxter’s island capacity, worsened a national intravenous fluid shortage, and led FDA to permit temporary imports from Ireland, Australia, Mexico, Canada and Germany. Sterile injectable and biologic capacity remains concentrated on a hurricane-exposed island. A pre-filed, pre-inspected ANDA portfolio in shortage-listed sterile injectables positions you for that, and the USD 15,000 statutory foreign-facility surcharge is the price of entry you should model from day one. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog